Redefining Chemoresistance: Natural Bioactives as Molecular Modulators at the Cancer-Tumor Microenvironment Interface.

1. Introduction

Therapeutic resistance remains one of the most pressing challenges in modern oncology, representing a critical barrier to the long-term success of cancer treatments [ 1 ]. Despite significant advances in drug development, molecular diagnostics, and targeted therapies, resistance to chemotherapy continues to limit patient survival and quality of life [ 2 , 3 ]. In both solid and hematologic malignancies, tumor cells frequently adapt to cytotoxic stress through a myriad of mechanisms, ultimately rendering standard chemotherapeutic regimens ineffective [ 4 ]. These mechanisms include increased drug efflux, enhanced deoxyribonucleic acid (DNA) repair capacity, apoptosis evasion, metabolic reprogramming, and epigenetic alterations [ 5 ]. However, recent insights suggest that the development of chemoresistance is not solely an intrinsic property of cancer cells, but also profoundly influenced by the complex and dynamic ecosystem in which these cells reside, the tumor microenvironment (TME) [ 6 ].

The TME, a highly heterogeneous and interactive network composed of stromal cells, immune cells, extracellular matrix (ECM) components, cytokines, and growth factors, plays a pivotal role in shaping cancer progression and therapeutic response [ 7 ]. This microenvironment not only facilitates tumor growth and invasion but also actively participates in the development of resistance through paracrine signaling, immune modulation, and the induction of phenotypic plasticity in tumor cells [ 8 ]. The bidirectional crosstalk between cancer cells and the TME fosters a milieu conducive to survival under therapeutic pressure, thereby contributing to both primary and acquired chemoresistance [ 9 ].

Considering the limitations of conventional monotherapies and the inherent complexity of resistance pathways, there is a growing interest in agents capable of simultaneously targeting multiple molecular and cellular processes [ 10 ]. Natural bioactive compounds, secondary metabolites derived from plants, fungi, bacteria, and marine organisms, have emerged as promising candidates in this regard [ 11 , 12 , 13 , 14 ]. Unlike synthetic drugs, which often act on a single target or pathway, many natural compounds possess broad-spectrum biological activities that enable them to modulate a wide array of signaling cascades implicated in cancer pathogenesis and treatment resistance [ 15 ].

Notably, several natural bioactives such as curcumin, resveratrol, quercetin, epigallocatechin gallate (EGCG), and sulforaphane have demonstrated the ability to interfere with key regulators of chemoresistance, including nuclear factor-kappa B (NF-κB), phosphoinositide 3-kinase/protein kinase B (PI3K/Akt), signal transducer and activator of transcription (STAT) 3, and hypoxia-inducible factors (HIFs) [ 16 ]. These compounds also exhibit anti-inflammatory, antioxidant, anti-angiogenic, and immunomodulatory properties, positioning them as ideal candidates for disrupting the protective mechanisms conferred by the TME [ 17 ]. In preclinical studies, many of these bioactives have been shown to sensitize resistant tumor cells to chemotherapeutic agents, reverse multidrug resistance phenotypes, and attenuate the pro-tumorigenic effects of stromal elements [ 18 , 19 , 20 ].

Given their pleiotropic nature, relatively low toxicity, and potential for synergistic interactions with standard therapies, natural bioactives are increasingly being investigated as adjuncts to existing cancer treatment protocols [ 21 ]. However, despite promising in vitro and in vivo findings, their clinical translation has been hampered by issues related to bioavailability, pharmacokinetics, and standardization [ 22 ]. Nevertheless, advancements in formulation technologies, such as nanoencapsulation and targeted delivery systems, are helping to overcome these limitations, opening new avenues for the integration of natural compounds into evidence-based oncology [ 23 , 24 , 25 ].

This review aims to synthesize current knowledge on the molecular mechanisms through which natural bioactive compounds influence chemoresistance, with a particular focus on their interactions at the cancer–TME interface. By exploring how these agents modulate key signaling pathways, cellular cross-talk, and environmental stress responses, we seek to provide a comprehensive framework for understanding their potential as multifaceted therapeutic tools. Ultimately, redefining chemoresistance through the lens of natural bioactives may offer novel strategies for improving treatment outcomes and overcoming one of the most formidable obstacles in cancer therapy.

2. Key Molecular Mechanisms Underlying Therapeutic Resistance

Tumor drug resistance arises from a complex interplay of cellular adaptations that enable cancer cells to survive even under aggressive therapeutic pressures. One of the most pivotal strategies employed by malignant cells is the evasion of apoptosis. Under normal physiological conditions, chemotherapeutic agents aim to induce programmed cell death via the intrinsic mitochondrial pathway. This involves mitochondrial outer membrane permeabilization, which initiates cytochrome c release and caspase cascade activation, ultimately leading to apoptosis. However, in resistant tumors, this pathway is frequently disrupted. Cancer cells often overexpress anti-apoptotic genes and proteins, which inhibit mitochondrial outer membrane permeabilization and prevent the apoptotic process. Simultaneously, key pro-apoptotic proteins are downregulated or mutated, effectively shifting the balance toward cell survival.

Oncogenes contribute further to this apoptotic evasion. A prime example is Astrocyte Elevated Gene 1, which drives resistance by promoting the translation of multidrug resistance protein 1 (MDR1) mRNA, thereby enhancing efflux of chemotherapeutics such as doxorubicin. This oncogene also activates adenosine monophosphate-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) signaling, initiating autophagy as a protective mechanism and mediating resistance to doxorubicin and 5-fluorouracil. Furthermore, it impairs retinoic acid receptor function and upregulates MET receptor tyrosine kinase and Aldehyde Dehydrogenase 3 Family Member A1, reinforcing resistance through multiple molecular axes [ 26 ]. Another oncogene implicated in chemoresistance is AXL receptor tyrosine kinase, frequently overexpressed in resistant tumors. It facilitates resistance through its interaction with downstream receptor tyrosine kinase (RTK) signaling pathways, including Epidermal Growth Factor Receptor (EGFR), human epidermal growth factor receptor (HER) 2, and 3, thus contributing to enhanced cell survival and adaptation [ 27 ].

Survival pathways activated downstream of RTKs further entrench resistance. The PI3K/AKT/mTOR and Mitogen-Activated Protein Kinase (MAPK) signaling cascades are central to these processes. PI3K, upon activation, catalyzes the formation of Phosphatidylinositol-3,4,5-trisphosphate, which recruits and activates AKT via phosphorylation by 3-phosphoinositide-dependent protein kinase-1 and mTORC (mammalian target of rapamycin complex) 2. Activated AKT promotes cell survival by inactivating pro-apoptotic targets such as B-cell lymphoma (BCL) 2-Associated agonist of cell death and caspase-9, while simultaneously activating mTORC1, which enhances protein synthesis and cellular proliferation. In parallel, the MAPK pathway activates nuclear transcription factors like E-twenty-six-like transcription factor 1 and cellular oncogene fos, leading to upregulation of cyclin D1 and anti-apoptotic proteins, including BCL-2 and myeloid cell leukemia (MCL) -1. The Janus kinase (JAK)/STAT pathway complements this network. Activated STAT3 and STAT5 transcriptionally induce anti-apoptotic and immunosuppressive genes, facilitating both tumor survival and immune evasion. NF-κB, another key signaling axis, is activated through IκB kinase degradation and supports tumor persistence through the transcription of pro-survival and pro-inflammatory genes. These pathways are not isolated; extensive crosstalk among them ensures signal redundancy and robustness, complicating therapeutic efforts. PI3K/AKT can amplify NF-κB signaling, while MAPK and JAK/STAT share transcriptional targets with overlapping biological outcomes [ 28 ].

In tandem with these survival networks, dysregulated autophagy plays a substantial role in resistance. Autophagy, a lysosome-mediated degradation process, allows cells to recycle damaged components and generate metabolic substrates necessary for energy production and redox balance. In cancer, autophagy is frequently upregulated under therapeutic stress, enabling cells to avert apoptosis and sustain their bioenergetic demands. Autophagy initiation is controlled by the Unc-51-like autophagy activating kinase 1 complex, inhibited by mTORC1 under nutrient-rich conditions. Inhibition of mTORC1, via starvation or targeted drugs, releases this complex, initiating autophagosome formation with the help of Vacuolar Protein Sorting 34 and Beclin-1. While mTOR inhibition may impede proliferation, it simultaneously triggers autophagy, creating a paradox in treatment strategies. Extracellular signal-regulated kinases (ERKs) 1 and 2 in the MAPK pathway also contribute by modulating autophagy-related proteins and transcription factors, reinforcing cell survival under stress [ 29 ].

One of the most prominent and well-characterized mechanisms of drug resistance involves increased drug efflux via ATP-binding cassette (ABC) transporters ( Figure 1 ). Among these, P-glycoprotein (P-gp)/ATP-binding cassette sub-family B member 1 (ABCB1) is the most well-known and frequently implicated in multidrug resistance (MDR). P-gp plays a physiological role in protecting tissues by pumping out xenobiotics and toxins, but in tumors, its overexpression contributes to chemotherapy failure. Notably, its regulation is influenced by transcriptional inputs from PI3K/AKT and NF-κB signaling pathways. Additionally, epigenetic alterations, such as hypermethylation of the ABCB1 promoter, can paradoxically increase P-gp expression [ 30 ].

Other transporters such as ABCG2 and ABCC1 also participate in MDR, handling a broad spectrum of anticancer drugs including anthracyclines, taxanes, and platinum compounds [ 31 ]. ABCG2, for instance, acts as a xenobiotic pump with a significant role in effluxing chemotherapeutics in resistant cancers [ 32 ]. These ABC proteins are not only expressed on the plasma membrane, but also in intracellular vesicles, and they critically influence the pharmacokinetics of anticancer agents in humans. Importantly, they are also found in extracellular vesicles, which participate in drug expulsion and the horizontal transfer of resistance phenotypes to other cells in the TME [ 33 ]. Across solid tumors, overexpression of ABC transporters, particularly P-gp, remains one of the most consistent features of acquired drug resistance [ 30 ].

DNA repair mechanisms and epigenetic modifications further enhance resistance ( Figure 1 ). DNA methyltransferases (DNMTs) catalyze the addition of methyl groups to cytosine residues in cytosine–phosphate–Guanine islands, silencing the expression of tumor suppressor genes such as tumor protein p53 and pro-apoptotic effectors like BAX. Meanwhile, histone deacetylases (HDACs) promote chromatin compaction and gene repression, counteracted by histone acetyltransferases that facilitate gene transcription through chromatin relaxation. These changes are not static; they are dynamically regulated by oncogenic signaling pathways and tumor-derived environmental cues. Moreover, non-coding RNAs, including microRNAs and long non-coding RNAs, contribute significantly to resistance by targeting genes involved in apoptosis, drug metabolism, and DNA repair. Dysregulation in the miRNA biogenesis machinery, such as aberrant activity of Drosha and Dicer, further disrupts microRNA profiles, exacerbating resistance. Notably, some microRNAs have been shown to increase P-gp expression, linking epigenetic regulation directly to drug efflux mechanisms [ 34 , 35 ].

Beyond genetic and epigenetic factors, metabolic reprogramming underlies another layer of tumor adaptability. Cancer cells frequently adopt aerobic glycolysis, a phenomenon known as the Warburg effect, in which glucose is converted into lactate despite sufficient oxygen availability, suggesting the beneficial effects of adopting a low-sugar diet [ 36 ]. This metabolic shift supports biosynthetic processes and ATP production needed for rapid proliferation. Additionally, mitochondrial adaptations enhance redox balance and bioenergetic flexibility, promoting cell survival even under nutrient-deprived and hypoxic conditions [ 37 ].

This schematic outlines key cellular and molecular mechanisms underlying drug resistance, including tumor microenvironment changes, epigenetic alterations, epithelial-to-mesenchymal transition (EMT), enhanced drug efflux, and increased DNA repair. Drug efflux transporters use ATP hydrolysis to expel chemotherapeutic agents (30), while upregulated DNA repair systems enable cancer cells to survive genotoxic therapies such as platinum-based drugs and topoisomerase inhibitors [ 30 , 38 , 39 ]. Abbreviations—ABC: ATP binding cassette; EGFR: epidermal growth factor receptor; ATP: adenosine triphosphate; DNA: deoxyribonucleic acid; RTK: receptor tyrosine kinases; CAF: cancer-associated fibroblast; TAM: tumor-associated macrophage; and HER 2: human epidermal growth factor receptor 2.

3. The Tumor Microenvironment as a Co-Regulator of Resistance

The TME is increasingly recognized as a pivotal co-regulator of cancer progression and therapeutic resistance. Composing a heterogeneous network of malignant cells, stromal components, immune infiltrates, and ECM, the TME forms a dynamic ecosystem that profoundly influences tumor biology ( Figure 2 ) [ 40 ].

At the core of tumor heterogeneity lies the presence of cancer stem cells (CSCs), a subpopulation endowed with self-renewal, differentiation capacity, and tumor-initiating potential [ 41 ]. These cells orchestrate tumor relapse and drug resistance through intrinsic features such as quiescence, enhanced DNA damage response, and overexpression of ABC transporters [ 39 ]. Molecularly, CSCs engage signaling pathways including wingless-type MMTV integration site family (Wnt)/β-catenin, Notch, Hedgehog, PI3K/AKT, and NF-κB, which promote survival, stemness, and inflammatory microenvironments conducive to therapy evasion [ 42 ]. Physiologically, CSCs often reside in specialized hypoxic niches within the tumor, where HIFs, primarily HIF-1α, mediate metabolic reprogramming to glycolysis and autophagy, supporting CSC maintenance and resistance [ 42 ]. Hypoxic stress also induces EMT, enhancing CSC invasiveness and metastatic potential [ 43 ]. Together, these molecular and environmental adaptations empower CSCs to survive cytotoxic assaults and contribute substantially to intratumoral heterogeneity and therapeutic failure [ 43 ].

Tumor-associated macrophages (TAMs) represent a key immunosuppressive cell population within the TME, arising from circulating monocytes recruited and polarized by tumor-derived signals ( Figure 2 ) [ 44 ]. Recent studies have elucidated mechanisms underlying TAM-mediated resistance, including the polarization of macrophages via signaling pathways such as STAT3/IL-10 and PI3K/AKT, which enhance the efficacy of immune checkpoint blockade when modulated [ 45 , 46 , 47 ]. Moreover, TAMs interplay with adipocytes within the TME, wherein adipocyte-secreted inflammatory cytokines activate NF-κB signaling in macrophages, linking obesity-associated inflammation to endocrine therapy resistance [ 48 , 49 ]. Effective management of obesity is essential, as the chronic inflammation associated with this condition has been implicated in the development or aggravation of various diseases, including cancer [ 50 , 51 , 52 , 53 , 54 , 55 ].

Cancer-associated fibroblasts (CAFs), the predominant stromal cell type in many solid tumors, originate from activated fibroblasts influenced by tumor-secreted cytokines such as transforming growth factor beta (TGF-β), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) 2, and can also derive from mesenchymal stem cells or other cell types via transdifferentiation [ 56 ]. These cells modulate tumor progression and resistance through diverse mechanisms, including remodeling the ECM, secreting growth factors and cytokines, and mediating metabolic crosstalk [ 57 ]. CAFs enhance CSC survival by activating pathways such as Wnt/β-catenin, NF-κB, and STAT3, thus promoting stemness and resistance to agents like oxaliplatin, 5-fluorouracil, gemcitabine, and cisplatin in colorectal, gastric, and pancreatic cancers [ 58 , 59 , 60 ]. Exosomes secreted by CAFs carry microRNAs and proteins that modulate tumor cell gene expression, induce autophagy, and facilitate drug resistance [ 61 , 62 , 63 , 64 , 65 , 66 ]. CAFs also regulate immune suppression by recruiting immunosuppressive cells and inducing their polarization via cytokines such as IL-6, TGF-β, and Insulin-like Growth Factor Binding Protein 7, further blunting anti-tumor immunity [ 57 ].

A notable CAF function is their involvement in promoting resistance to radiotherapy [ 67 ]. They do so by secreting protective cytokines (e.g., IL-6, TGF-β), facilitating autophagy in cancer cells, and direct cell contact, activating survival pathways such as β1 integrin and Focal Adhesion Kinase (FAK) signaling [ 42 ]. CAFs are intrinsically radioresistant, partly due to defects in p53/p21 and high expression of Survivin, and radiotherapy itself can induce a secretory phenotype in CAFs characterized by pro-tumorigenic cytokines like IL-6, IL-8, and osteopontin that enhance tumor proliferation and immunosuppression post-irradiation [ 57 ]. Additionally, CAFs upregulate immune checkpoint molecules in cancers such as colorectal and lung adenocarcinoma, promoting immune escape [ 68 , 69 ]. They also contribute to ECM remodeling and aberrant angiogenesis, limiting immune cell infiltration and fostering an immunosuppressive milieu [ 70 , 71 , 72 , 73 ].

Endothelial cells and cancer-associated adipocytes (CAAs), though less abundant than CAFs, are critical in shaping tumor progression and therapy resistance. Tumor endothelial cells facilitate aberrant neovascularization and vasculogenesis, which can exacerbate hypoxia and promote resistance by limiting T cell infiltration [ 57 ]. Vascular endothelial growth factor (VEGF), secreted by endothelial and tumor cells, is central to angiogenesis and suppresses dendritic cell maturation, reducing antigen presentation and enhancing programmed cell death 1 ligand 1 (PD-L1) expression on immune cells, thereby impairing effective T cell responses [ 74 ]. ECM remodeling is exacerbated by hypoxia and HIF-1α signaling, which upregulate collagen and fibrosis-associated genes, further reinforcing an immunosuppressive and pro-metastatic niche [ 75 ]. Enzymes like lysyl oxidase cross-link ECM fibers, increasing tumor stiffness and acting as a physical barrier to therapeutics [ 76 ]. Additionally, aberrant ECM contributes to metabolic stress and activates integrin-FAK signaling pathways in tumor cells, promoting survival and therapy resistance [ 77 ].

Hypoxia, a hallmark of solid tumors driven by inadequate vascularization relative to rapid tumor growth, activates HIFs, mainly HIF-1α, which orchestrate transcriptional programs that regulate angiogenesis, metabolic adaptation, immune modulation, and ECM remodeling [ 76 ]. Stabilized HIF-1α induces proangiogenic factors such as VEGF, PDGF, FGF, angiopoietins, and matrix metalloproteinases (MMPs), driving the formation of abnormal, leaky vasculature that facilitates invasion, metastasis, and therapy resistance [ 78 , 79 ]. Additionally, HIF-1α modulates metabolic reprogramming toward glycolysis, generating acidic microenvironments rich in lactate that suppress immune effector cells while promoting regulatory populations like regulatory T cells and myeloid-derived suppressor cells (MDSCs) [ 42 ]. Reactive oxygen species (ROS) and endoplasmic reticulum stress further regulate HIF signaling, adding layers of complexity to tumor adaptation [ 80 ]. The temporal “HIF switch” from HIF-1α in acute hypoxia to HIF-2α in chronic states enables sustained vascular maturation and energy balance, reinforcing tumor progression [ 81 ]. Hypoxia also induces immune checkpoints such as PD-L1, Human Leukocyte Antigen-G, CD47, and V-domain Ig Suppressor of T cell Activation, which inhibit T cell and macrophage function and facilitate immune evasion [ 42 ].

Collectively, the interplay among CSCs, TAMs, CAFs, endothelial cells, CAAs, and the ECM under hypoxic and immunosuppressive conditions drives tumor heterogeneity, immune escape, angiogenesis, and resistance to diverse therapies [ 82 ]. These reciprocal interactions and adaptive mechanisms underscore the complexity of targeting the TME to overcome resistance. While targeting single components like immune checkpoints or angiogenesis has yielded limited success, integrative strategies that consider the multifactorial nature of TME regulation are essential for improving clinical outcomes. Emerging technologies such as single-cell RNA sequencing hold promise for unraveling stromal-immune crosstalk and identifying novel therapeutic targets [ 57 ].

Lastly, emerging evidence highlights the role of gut microbiota in oncogenesis and therapy resistance, particularly in colorectal cancer [ 83 ]. Dysbiosis, characterized by the predominance of colibactin-producing Escherichia coli , induces DNA damage, ROS generation, and chromosomal instability, contributing to tumor progression and chemoresistance. Targeting such microbial factors may represent novel adjunctive strategies in cancer treatment [ 84 , 85 ].

The TME drives tumor heterogeneity, immune escape, and resistance to chemotherapy, radiotherapy, and immunotherapy. Stromal fibroblasts, immune cells, ECM components, and vasculature activate pro-survival signaling in tumor cells, remodel the ECM to hinder drug delivery, and promote VEGF-independent vascularization. CAAs secrete IL-6, tumor necrosis factor alpha (TNF-α), and insulin-like growth factor-1, stimulating proliferative and survival pathways, metabolic reprogramming, and chronic inflammation through the autotaxin–lysophosphatidic acid pathway. Tumor cells evade immune surveillance by downregulating tumor-associated antigens and major histocompatibility complex molecules, overexpressing immune checkpoint ligands, shedding antigens, and releasing immunosuppressive mediators such as TGF-β, IL-10, and PD-L1, resulting in cytotoxic T lymphocyte exhaustion and tumor persistence. TAMs further contribute to tumor progression, metastasis, angiogenesis, invasion, and CSC expansion through cytokine and growth factor release. CCL8 recruits monocytes, induces CSF-1 production to maintain TAM survival and proliferation, and binds SIGLEC1 to enhance tumor cell motility; inhibition of the CSF-1/CSF-1 receptor axis reduces angiogenesis. IL-1 facilitates metastatic cell recruitment and colonization. Due to their plasticity, TAMs exhibit distinct phenotypes: M1-like TAMs mediate tumoricidal, pro-inflammatory effects, whereas M2-like TAMs promote tumor growth, invasion, angiogenesis, and immune suppression via IL-10, TGF-β, VEGF, and PD-L1. M2-like TAMs also enhance therapeutic resistance by protecting tumor cells from immune destruction, inducing abnormal vasculature, and inhibiting CTL activity [ 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 ]. Abbreviations—TME: tumor microenvironment; ECM: extracellular matrix; CAAs: cancer-associated adipocytes; MHC: major histocompatibility complex; CCL8: C-C motif chemokine ligand 8; MDSC: myeloid-derived suppressor cell; TGF-β: transforming growth factor beta; Treg: regulatory T cell; PD-L1: programmed cell death 1 ligand 1; VEGF: vascular endothelial growth factor; TAM: tumor-associated macrophage; SIGLEC1: sialic acid-binding immunoglobulin-type lectin 1; IL-1: interleukin-1; IL-6: interleukin-6; IL-10: interleukin-10; TNF– α: tumor necrosis factor-alpha; IGF-1: insulin-like growth factor-1; EGF: epidermal growth factor; PDGFβ: platelet-derived growth factor beta; CSC: cancer stem cell; CSF1: colony-stimulating factor-1; CSF1R: colony-stimulating factor 1 receptor; CTL: cytotoxic T lymphocytes; HIF-1α: hypoxia-inducible factor 1-alpha; and VEGF-A: vascular endothelial growth factor A.

4. Natural Bioactive Compounds with Functional Evidence

Since the interconnected mechanisms described above form a strong barrier to effective cancer treatment, there is growing interest in combination therapies that target multiple pathways, such as autophagy, epigenetic alterations, drug efflux, and dysbiosis, to overcome resistance and improve patient outcomes [ 100 ]. Emerging nutritional strategies, including calorie restriction and ketogenic or plant-based diets (i.e., Mediterranean diet), aim to disrupt cancer metabolism and counteract resistance, supporting their use as valuable adjuncts in oncology and therapeutic approaches for other conditions [ 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 ]. These effects are largely attributed to the rich content of bioactive compounds in such diets [ 110 , 111 ], including polyphenols, alkaloids, terpenoids, diterpenes, bioactive lipids, marine-derived metabolites and anthraquinones ( Figure 3 ), which modulate key pathways such as inflammation, oxidative stress, DNA repair, and apoptosis ( Figure 4 ) [ 112 , 113 , 114 ].

4.1. Polyphenols

Polyphenols represent a broad spectrum of plant-based secondary metabolites recognized for their ability to regulate oxidative balance, immune responses, and carcinogenic pathways [ 137 ]. Beyond their well-established antioxidant roles, these compounds modulate inflammation, promote apoptosis, and influence epigenetic and transcriptional landscapes. Their biological activities are often mediated through signaling cascades involving NF-κB, STAT3, PI3K/Akt, and MAPK, which are frequently dysregulated in cancer [ 138 , 139 , 140 ].

Curcumin, a non-flavonoid polyphenol from Curcuma longa , exerts potent anti-inflammatory and anticancer effects through diverse molecular targets. It inhibits NF-κB signaling by stabilizing the inhibitor of nuclear factor kappa B alpha and blocking the nuclear translocation of NF-κB subunits, thereby downregulating pro-inflammatory mediators such as IL-1β and Cyclooxygenase (COX)-2 [ 141 ]. In breast cancer cells, it reduces p100/p52 expression, limiting proliferation and invasion [ 142 ]. Additionally, curcumin disrupts STAT3 activation by preventing its phosphorylation and DNA-binding activity, suppressing the expression of survival genes like Mcl-1, X-linked inhibitor of apoptosis protein gene, and PD-L1 [ 143 , 144 , 145 ]. It also enhances antitumor immunity by increasing CD8 + T cell infiltration and modulating the TME [ 146 ].

On an epigenetic level, curcumin inhibits DNMTs and HDACs, alters histone modifications, and restores tumor suppressor gene expression [ 147 , 148 , 149 ]. It also regulates a broad array of non-coding RNAs, particularly microRNAs and long non-coding RNAs, which influence cancer cell proliferation, invasion, metastasis, and apoptosis in several tumor types, including breast, gastric, ovarian, and colorectal cancers (MING). Through this modulation, curcumin can reverse chemoresistance, enhancing the efficacy of conventional anticancer therapies [ 150 ].

Resveratrol, another polyphenol found in grapes and berries, is known for its capacity to inhibit cancer progression by disrupting NF-κB-mediated transcription of inflammatory and anti-apoptotic genes, including COX-2, Bcl-2, and MMP-9 [ 151 , 152 , 153 ]. It also targets STAT3 and ERK pathways, downregulating IL-6 production and delaying tumor growth in pancreatic models [ 154 ]. In cholangiocarcinoma, inhibition of STAT3 is associated with enhanced autophagy via BECLIN-1 [ 155 ]. Additionally, resveratrol hinders EMT and cancer stemness by downregulating CD44, CD133, and SLUG through modulation of PI3K/Akt and Smad signaling [ 124 , 125 , 156 , 157 ]. On the epigenetic level, it activates Sirtuin 1 (SIRT1) gene, reshapes histone acetylation patterns, alters DNA methylation, and modulates microRNAs, collectively reprogramming gene expression linked to cell cycle control and apoptosis [ 158 , 159 ].

EGCG, the primary catechin in green tea, inhibits tumor-promoting pathways by blocking NF-κB and STAT3 activation, thus reducing the transcription of IL-6, MMP-9, and CD44 [ 160 , 161 , 162 ]. EGCG also suppresses the PI3K/Akt axis, leading to activation of p53, p21, Bax, and caspases, while downregulating anti-apoptotic proteins like Bcl-2 [ 126 ]. Importantly, EGCG exerts significant epigenetic control by inhibiting DNMTs and HDACs, reactivating silenced tumor suppressors, and regulating EMT-associated microRNAs [ 163 , 164 , 165 ]. Furthermore, it alters the tumor immune landscape by targeting MDSCs through modulation of the Arginase 1 (Arg-1)/inducible nitric oxide synthase/STAT3 axis and related signaling pathways [ 166 ].

4.2. Alkaloids

Alkaloids like berberine (BBR) and vincristine are known for their strong anticancer properties, primarily due to their ability to modulate key intracellular signaling networks that govern angiogenesis inhibition, mitochondrial stability, cell cycle progression, and mechanisms of multidrug resistance [ 167 ]. BBR, a naturally occurring benzylisoquinoline alkaloid with a characteristic yellow crystalline appearance, is present in various parts of medicinal plants, including roots, bark, leaves, and rhizomes [ 168 ]. On a mechanistic level, BBR initiates apoptosis and mitochondrial impairment by elevating intracellular ROS, prompting cytochrome c release, and activating caspase-3 through the upregulation of Growth Arrest and DNA Damage-inducible protein 153 (GADD153) and the involvement of the PI3K/Akt/mTOR and AMPK–p53 axes [ 169 ]. In cancers such as cervical, thyroid, and glioblastoma, it further promotes intrinsic apoptotic signaling, increases intracellular calcium levels, and shifts the Bax/Bcl-2 ratio in favor of apoptosis [ 170 ].

BBR also plays a crucial role in halting cell cycle progression at multiple checkpoints (G0/G1, G1, and G2/M), largely by increasing the expression of cyclin-dependent kinase inhibitors CIP1/p21 and Kip1/p27, while downregulating cyclins A and D1 and cyclin-dependent kinases 1, 2, 4, and 6 [ 171 ]. These effects are reinforced by the suppression of murine double minute 2, which allows for enhanced stabilization and activation of the p53 protein, along with the regulation of specific microRNAs (miR-23a and miR-214-3p) and interactions with calmodulin [ 172 ]. Moreover, BBR has been shown to potentiate the effects of multiple chemotherapeutic agents, including cisplatin, doxorubicin, 5-fluorouracil, niraparib, icotinib, and Osimertinib, and to increase tumor sensitivity to radiotherapy [ 173 ]. One major contributor to these effects is its ability to downregulate the expression of the MDR1 gene, which encodes the P-gp efflux pump, a key factor in chemotherapy resistance [ 174 ]. Notably, in the setting of Candida albicans infection, BBR takes advantage of a pH-dependent reversal in Mdr1p transporter function, typically an efflux mechanism, to enable its own intracellular accumulation, offering a unique antifungal strategy [ 175 ].

Vincristine and vinblastine, two Vinca alkaloids derived from Catharanthus roseus , exhibit strong cytotoxic effects by interfering with microtubule formation, thereby impairing mitotic spindle assembly and inducing cell cycle arrest at the G2/M transition via cyclin B1 accumulation [ 176 , 177 ]. This disruption ultimately leads to apoptosis through mitochondrial pathways, involving c-Jun N-terminal kinase-mediated activation of pro-apoptotic proteins such as Bax and Bak, mitochondrial outer membrane permeabilization, and caspase-3 and -9 cleavage [ 127 ]. Beyond their antimitotic actions, these compounds influence additional signaling pathways, such as NF-κB signaling by facilitating inhibitor of nuclear factor kappa B alpha degradation, enabling nuclear translocation of NF-κB and transcriptional control over genes related to cell death. Furthermore, vincristine regulates a variety of microRNAs, including miR-155, miR-122, miR-1179, and miR-222-3p, which target critical survival pathways such as PI3K/Akt, MAPK, and JAK/STAT, thereby promoting apoptosis and overcoming resistance in cancer cells [ 178 ].

4.3. Terpenoids and Diterpenes

Among natural bioactive compounds, terpenoids such as andrographolide and paclitaxel have demonstrated promising therapeutic effects in resistance models, particularly through their roles in autophagy modulation and microtubule dynamics. Andrographolide, a diterpenoid lactone extracted from Andrographis paniculata , exhibits diverse pharmacological properties, including anti-inflammatory, anti-diabetic, and anticancer activities [ 179 ]. Mechanistically, it interferes with pro-survival autophagic signaling by inhibiting the PI3K/AKT/mTOR pathway and activating the c-Jun N-terminal kinase cascade, thereby reducing HIF-1α expression, a key regulator of tumor progression under hypoxia [ 180 ]. This action is associated with mitochondrial dysfunction, as shown by increased p53 expression, an elevated Bax/Bcl-2 ratio, and enhanced radiosensitivity in tumor cells [ 181 ]. Furthermore, andrographolide exerts anti-angiogenic and anti-inflammatory effects by downregulating NF-κB, Erk1/2, nicotinamide adenine dinucleotide phosphate oxidase, ROS, and P38 MAPK, while concurrently activating activator protein-1 [ 182 ]. Its ability to inhibit oncogenic pathways such as NF-κB, HIF-1, and JAK/STAT has been observed across various cancer types, including lung, breast, ovarian, and colorectal malignancies [ 182 , 183 , 184 , 185 ].

Paclitaxel, another diterpenoid of natural origin, was first isolated from the bark of Taxus brevifolia and is known for its unique mechanism of stabilizing microtubules [ 128 ]. By binding to the β-tubulin subunit and promoting M-loop conformational changes, it enhances lateral protofilament interactions and induces mitotic arrest [ 186 , 187 ]. Additionally, paclitaxel triggers autophagy in various cancers by increasing expression of Beclin-1, Autophagy protein 5, and microtubule-associated protein 1 light chain 3, contributing to both apoptotic and caspase-independent cell death pathways [ 188 , 189 ]. Due to sustainability concerns, alternative production approaches, including biosynthesis and tissue culture, are being actively explored [ 190 ].

4.4. Bioactive Lipids and Marine-Derived Metabolites

Marine-derived bioactive compounds such as fucoxanthin (FX) and kahalalide F (KF) demonstrate significant promise in modulating cellular responses to mitochondrial dysfunction and non-canonical apoptosis [ 129 ]. FX, a carotenoid abundant in brown algae, protects cells from mitochondrial stress by preserving membrane potential, enhancing ATP synthesis, and reducing ROS overproduction through the activation of signaling cascades such as Akt/glycogen synthase kinase 3β/Tyrosine-protein kinase Fyn and Nuclear Factor Erythroid 2-Related Factor 2/Heme Oxygenase-1 [ 191 ]. FX counteracts toxin-induced mitochondrial dysfunction, such as that caused by Ochratoxin A, by restoring the activity of respiratory complexes I and III, upregulating mitochondrial genes (ND1, ND5, CO-I), and activating mitochondrial biogenesis via peroxisome proliferator-activated receptor gamma coactivator 1-α and nuclear respiratory factor 1 [ 192 ]. Its metabolite fucoxanthinol exhibits superior efficacy in restoring antioxidant defenses and mitophagy markers such as PTEN-induced kinase 1 and Parkin, attenuating both ROS and intrinsic apoptotic signaling via caspase-9, -3, and Bax/Bcl-2 modulation [ 130 , 192 ]. Additionally, FX induces apoptosis-inducing factor-dependent, caspase-independent apoptosis, modulates mitochondrial dynamics, and mitigates endoplasmic reticulum stress-related apoptosis via GADD153/glucose-regulated protein 78 suppression [ 130 , 193 ].

KF, a cyclic depsipeptide originally isolated from Bryopsis spp., induces rapid mitochondrial membrane depolarization, lysosomal permeabilization, and endoplasmic reticulum dilation, culminating in oncosis-like, caspase-independent cell death [ 194 , 195 ]. Unlike traditional apoptosis, KF disrupts cellular architecture via swelling, blebbing, and lipid bilayer dissolution, possibly mediated by HER3 interference and AKT pathway suppression [ 196 ]. Its selectivity for tumor cells and independence from MDR1 or BCL2 pathways highlight its therapeutic potential in apoptosis-resistant cancers [ 197 , 198 ].

Building on the anticancer effects of marine-derived compounds, Nortopsentins, bis-indolyl alkaloids from marine sponges, demonstrate potent cytotoxic and anti-inflammatory activities. These compounds and their derivatives are active against a broad spectrum of cancer cell lines, including lung, breast, colon, ovarian, pancreatic, liver, bladder, prostate, melanoma, renal, sarcoma, and uterine cancers [ 131 ]. Their bis-indole scaffold, often containing an imidazole moiety, allows them to target key signaling pathways by inhibiting cyclin-dependent kinase 1, inducing cell cycle arrest at G0/G1 or G2/M phases, and triggering apoptosis through nuclear condensation and membrane blebbing. In colorectal cancer stem cells, adaptive activation of CD44v6-mediated Wnt signaling can occur, but co-treatment with checkpoint Kinase 1 inhibitors like rabusertib disrupts this pathway and promotes apoptosis in both resistant and non-resistant cell populations, highlighting the versatility of Nortopsentin derivatives in targeting multiple oncogenic mechanisms [ 194 ].

4.5. Anthraquinones and Cobalamins

Anthraquinones, naturally occurring compounds in medicinal plants, exhibit neuroprotective, anti-inflammatory, anticancer, hepatoprotective, and anti-aging activities, largely through modulation of ROS [ 132 ]. They inhibit tumor growth by targeting key molecular pathways and proteins, including kinases, topoisomerases, telomerases, matrix metalloproteinases, and G-quadruplex DNA, disrupting processes critical for cancer cell survival. Certain derivatives, such as 1,3-dihydroxy-9,10-anthraquinones, induce G2/M arrest and apoptosis in cancer cells, while tetracyclic anthraquinone–pyridine hybrids show potent activity against both drug-sensitive and multidrug-resistant leukemia cells, suggesting potential to overcome chemoresistance [ 133 ]. Safety concerns persist, as compounds like rhein and emodin have been linked to hepatotoxicity, reproductive toxicity, and developmental defects, and chronic laxative use has been associated with melanosis coli and rare irreversible tissue changes [ 199 ]. Complementary strategies, such as cobalamins (C 63 H 88 CoN 14 O 14 P), which are vitamin B 12 derivatives, can enhance anticancer efficacy by selectively targeting tumor cells and improving delivery; for instance, their use in phthalocyanine-based photodynamic therapy reduces dark toxicity and increases therapeutic performance [ 200 , 201 ].

5. Emerging Strategies for Therapeutic Combination

Despite notable advancements in cancer therapies, conventional treatments continue to face significant challenges, including nonspecific cytotoxicity, inadequate tumor targeting, and the recurrent development of resistance to drugs [ 202 ]. These limitations often lead to suboptimal therapeutic outcomes, relapse, and treatment failure. To address these concerns, growing attention has been given to integrating natural bioactive compounds, particularly those sourced from plants and marine organisms, into standard cancer therapies [ 203 ]. These molecules are recognized for their multitargeting abilities and generally exhibit lower toxicity compared to synthetic drugs [ 202 , 204 , 205 ]. They can influence immune mechanisms, promoting programmed cell death, hindering tumor cell proliferation, and improving tumor sensitivity to conventional chemotherapy. When used in combination with standard anticancer drugs, they often generate synergistic effects that can mitigate toxicity and help overcome multidrug resistance [ 206 ].

Numerous natural compounds have demonstrated enhanced anticancer efficacy when administered alongside chemotherapeutics ( Table 1 ). For instance, EGCG intensifies the effects of cisplatin and paclitaxel by increasing DNA damage and lowering oxidative stress levels [ 207 , 208 ]. Curcumin, widely known for its anti-inflammatory and antineoplastic effects, acts through mechanisms including NF-κB inhibition. Nonetheless, its antioxidant properties may counteract ROS-dependent drugs such as doxorubicin [ 209 ]. Even so, curcumin remains effective when co-administered with drugs like paclitaxel, melphalan, and prednisone, especially in gastric cancer and multiple myeloma, owing to its ability to block NF-κB signaling [ 210 ]. In fact, adherence to the Mediterranean diet has been associated with protective effects against gastric cancer, largely attributed to the bioactive compounds present in plant-based foods [ 211 ].

Several additional compounds work through complementary biological pathways. For example, gambogic acid and solamargine have been shown to increase the impact of cisplatin in non-small-cell lung cancer (NSCLC) by repressing Hedgehog signaling. Similarly, sulforaphane and gefitinib exert comparable effects on this pathway [ 212 ]. Hederagenin enhances cancer therapy outcomes by modulating autophagy markers such as microtubule-associated protein light chain 3 I and II. Resveratrol, sourced from grapes, bolsters the therapeutic action of paclitaxel by inhibiting anti-apoptotic proteins like Bcl-2 and survivin through mTOR pathway suppression. Flavonoids such as apigenin boost cisplatin-induced apoptosis and reduce cancer stem cell fractions via p53-mediated mechanisms [ 213 ]. Other compounds, including dehydrobruceine B, intensify the effectiveness of platinum-based chemotherapy by inducing mitochondrial oxidative stress [ 214 , 215 ]. Notably, curcumin also exhibits protective effects on healthy tissues during cisplatin treatment in NSCLC, supporting its dual role as a sensitizer and a cytoprotective agent [ 216 ].

Despite these promising results, many natural compounds face substantial pharmacokinetic challenges. Their clinical application is hindered by issues like low aqueous solubility, instability in physiological environments, limited absorption, and short systemic circulation, which collectively reduce therapeutic efficacy and necessitate higher, potentially toxic, dosages [ 217 ]. To address these drawbacks, a variety of advanced drug delivery technologies have been introduced, such as nanocarriers, liposomes, and targeting systems [ 218 ].

Nanoparticles (NPs), generally sized between 1 and 100 nanometers, offer numerous benefits. Their high surface area and small dimensions support improved drug encapsulation, sustained release, and preferential accumulation in tumor tissues via the enhanced permeability and retention effect. Furthermore, they can be surface-modified with targeting molecules, such as antibodies, peptides, or folate, to bind tumor-associated receptors like HER 2, EGFR, the transferrin receptor, and αvβ3 integrins, enhancing targeted delivery and minimizing off-target toxicity [ 219 ].

The use of environmentally friendly NPs derived from marine organisms further expands therapeutic possibilities. For example, silver NPs produced from the green alga Caulerpa taxifolia prompt apoptosis in lung cancer cells through membrane damage. Similarly, jellyfish-derived gold NPs inhibit the activity of oncogenic kinases like AKT and ERK in HeLa cells. Other cases include copper oxide nanoparticles synthesized by Rhodotorula mucilaginosa and chitin–silver hybrids from shrimp shells, which promote apoptosis through Bax and caspase activation while suppressing anti-apoptotic proteins like Bcl-2 and Bcl-xL (JEONG). These marine-based nanocarriers offer both inherent anticancer properties and enhanced drug transport functions.

Liposomes, built from lipid bilayers, represent another key nanocarrier with clinical relevance. They protect encapsulated drugs from degradation and can carry both hydrophobic and hydrophilic agents. PEGylation, modification with polyethylene glycol, prolongs systemic circulation by reducing immune detection, improving drug accumulation at the tumor site [ 220 ]. A prominent example is PEGylated liposomal doxorubicin, which demonstrates reduced heart toxicity compared to unencapsulated doxorubicin. Innovations in liposome design have led to tumor-specific targeting. For instance, liposomes conjugated with antibodies against melanoma-associated antigen MAGE-A1 have shown improved delivery of doxorubicin in experimental models [ 221 ]. FF-10832, a PEGylated liposomal version of gemcitabine, has shown favorable pharmacokinetics, including prolonged half-life, better tumor uptake, and reduced hematologic side effects [ 220 ]. Stimuli-responsive delivery systems represent another frontier. These “smart” carriers are engineered to respond to tumor microenvironmental cues such as low pH, redox gradients, or specific enzymes. pH-sensitive liposomes and enzyme-cleavable polymeric NPs allow precise drug release at tumor sites while sparing healthy tissues [ 222 ].

Beyond liposomes, solid lipid Nps, nanoemulsions, and dendrimers have been developed to enhance oral bioavailability and avoid first-pass metabolism. These systems shield active agents from enzymatic degradation and improve uptake by optimizing parameters such as particle size, surface charge, and lipid content [ 217 , 222 ]. Additionally, modifying drug molecules into prodrugs or optimizing their chemical structure can further improve metabolic stability. Emerging studies have also highlighted the role of gut microbiota in modulating drug metabolism and absorption. Microbial enzymes can modify drug molecules through hydrolysis, reduction, or deconjugation, influencing therapeutic activity before systemic circulation begins [ 223 ]. The effects of these microbial transformations can vary based on diet, age, antibiotic use, and host genetics, complicating pharmacokinetic predictability. Tailoring treatment strategies according to microbiome profiles could significantly enhance personalized medicine approaches.

Nanotechnology has also transformed immunotherapy by improving the delivery of checkpoint inhibitors, vaccines, and immune modulators [ 224 ]. Liposomes and nanoparticles have been utilized to transport agents like anti-programmed cell death protein-1 (PD-1), anti-PD-L1, and anti-cytotoxic T-lymphocyte-associated protein-4, improving their tumor localization and enhancing therapeutic results [ 225 ]. Targeted nanocarriers equipped with antibodies have improved drug delivery in melanoma models, although excessive targeting affinity may increase off-target interactions [ 221 ].

Additional methods include the use of tumor-targeting peptides that bind specifically to integrins overexpressed in tumor vasculature, enhancing nanocarrier penetration and retention [ 219 ]. Multifunctional “theranostic” systems, combining therapeutic and diagnostic components, are emerging as valuable tools for real-time monitoring of treatment distribution and efficacy. These systems seek to personalize drug release both spatially and temporally, reduce off-target exposure, and adapt therapy to individual patient needs.

Finally, oral lipid-based platforms, such as self-emulsifying drug delivery systems, have demonstrated improvements in systemic bioavailability by enhancing lymphatic transport and bypassing liver metabolism. Co-delivery of chemotherapeutic agents with efflux pump blockers or modulators of the tumor microenvironment through these platforms further combats resistance by facilitating higher intracellular drug concentrations.

6. Current Challenges and Future Perspectives

Although bioactive compounds such as curcumin, resveratrol, and EGCG have demonstrated promising synergy with conventional chemotherapeutics in preclinical studies, translating these results to clinical efficacy remains a major hurdle. Pharmacokinetic differences between animal models and humans frequently lead to discrepancies in drug absorption, distribution, metabolism, and excretion, resulting in limited clinical success [ 242 , 243 ]. Curcumin, in particular, suffers from poor bioavailability and rapid metabolic clearance in humans, which severely restricts its systemic exposure despite encouraging in vitro outcomes [ 244 , 245 ]. Consequently, updated translational approaches, such as patient-derived xenografts, 3D tumor organoids, and early-phase pharmacokinetic profiling, are increasingly advocated to better simulate human biology and optimize dosing strategies [ 246 , 247 , 248 ]. Ochoa et al. [ 134 ] performed a study where they examined the combination of curcumin and resveratrol with chemotherapy in colorectal and breast cancer and exhibited improved tolerability but did not achieve statistically significant efficacy, largely due to suboptimal dosing and bioavailability challenges.

Another critical barrier lies in the standardization and reproducibility of botanical extracts. Unlike synthetic drugs, natural products are inherently complex mixtures whose chemical profiles can vary based on geographic origin, harvest season, and extraction protocols [ 249 ]. This variability undermines consistency in experimental results and complicates regulatory approval [ 250 , 251 ]. To address this, the ConPhyMP guidelines have been introduced to promote standardized practices in botanical authentication, chromatographic techniques (including fingerprinting), and quantification of key marker compounds [ 252 ]. Despite widespread recognition of these standards, many research laboratories still lack the capacity or standardized protocols to implement them fully, resulting in ongoing discrepancies between batches and studies.

Technological advances in nanocarrier design, including NPs and liposomes, hold great promise for overcoming pharmacokinetic limitations [ 253 ]. Novel platforms such as erythrocyte membrane-coated NPs and glycoprotein-targeted mesoporous silica systems have demonstrated improved drug stability, evasion of immune surveillance, and controlled release in tumor-specific environments (i.e., pH-sensitive or enzyme-triggered), showing efficacy in lung cancer models [ 24 , 245 , 254 , 255 , 256 ]. Liposomal formulations incorporating curcumin and paclitaxel via inhalation have likewise induced selective apoptosis in NSCLC models while sparing normal lung tissue [ 257 ]. These developments illustrate how nanotechnology can enhance both the delivery and therapeutic index of bioactive–chemotherapy combinations [ 258 , 259 ].

Combining natural compounds with immunotherapy is another emerging frontier [ 260 ]. Certain phytochemicals act as immune checkpoint modulators [ 261 ]; for example, apigenin downregulates PD-L1 expression and berberine promotes PD-L1 degradation, thereby enhancing cytotoxic T-cell activity [ 254 ]. EGCG has been shown to prevent chemotherapy-induced upregulation of PD-L1 via the JAK2/STAT1 signaling axis, preserving effector CD8+ T-cell function in models of resistant lung cancer [ 262 ]. Moreover, co-administration of apigenin with anti-PD-1 therapy in murine Lewis lung carcinoma models enhanced T-cell infiltration and tumor regression, suggesting that phytochemicals may effectively augment the immune effects of checkpoint inhibitors [ 254 ].

Personalized oncology further expands the potential of these combined strategies by tailoring treatments based on individual molecular and microbiome profiles [ 263 , 264 ]. The gut microbiota plays a pivotal role in modifying drug metabolism and immune responses; microbial enzymes can convert certain phytochemicals into active or inactive metabolites, influencing therapeutic efficacy and toxicity [ 265 , 266 ]. Consequently, microbiome-aware drug formulation, incorporating probiotics, prebiotics (i.e., by nutrition), or microbiome-preserving nanoparticles, could improve bioavailability and reduce variability across patient populations [ 267 , 268 ]. Similarly, tumor profiling that includes PD-L1 status, microsatellite instability, and tumor mutational burden could guide the selection of optimized bioactive–immunotherapy combinations, supporting more personalized and potentially effective regimens [ 269 , 270 , 271 ].

Furthermore, theranostic nanoparticle systems that co-encapsulate diagnostic imaging agents and therapeutic payloads offer real-time monitoring of drug distribution and response [ 272 ]. These smart carriers can adjust release kinetics based on imaging feedback and pharmacodynamic markers, forming the basis of closed-loop therapeutic systems that personalize dosing and minimize off-target toxicity [ 273 , 274 ].

Taken together, the current challenges and future perspectives in integrating natural bioactives into cancer therapy can be summarized by three key priorities: 1) enhancing translational predictability via advanced human-relevant models and robust pharmacokinetic data; 2) ensuring reproducibility and regulatory compliance through standardized botanical preparations like those recommended by ConPhyMP; and 3) advancing precision therapy using smart nanocarriers capable of delivering synergistic bioactive and chemotherapeutic agents in an immunologically informed, patient-specific manner [ 275 ]. These comprehensive strategies have the potential to transform preclinical findings into clinically impactful treatments.

7. Conclusions

In the context of growing therapeutic resistance, natural bioactive compounds have demonstrated substantial potential to influence both intrinsic and microenvironment-driven mechanisms that allow cancer cells to survive, adapt, and evade treatment. Their multitarget nature, encompassing effects on cell death regulation, stress responses, immune modulation, and stromal interactions, positions them as ideal candidates for complementary therapy. Unlike single-target synthetic agents, these compounds can act on various levels simultaneously, addressing the complexity of resistance in a more holistic way.

This review has highlighted key chemical families, such as polyphenols, alkaloids, terpenoids, and marine-derived metabolites, that show functional relevance in resistance models. The integration of these agents with conventional chemotherapy, supported by advances in delivery systems and pharmacokinetic improvements, may help overcome the limitations of current treatment protocols. However, to move from experimental promise to clinical reality, several challenges remain. These include the need for standardized extracts, consistent bioavailability, and robust clinical trial data.

Ultimately, harnessing the therapeutic potential of natural bioactives requires a transdisciplinary approach. Collaboration between molecular researchers, pharmacologists, clinicians, and nutriologists is essential to unlock new therapeutic pathways and provide more personalized, effective, and less toxic options for cancer patients. Natural bioactives do not replace conventional therapy, but they may be key allies in redefining resistance and improving long-term outcomes.

Acknowledgments

The authors are grateful to Universidad UTE for their support.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Author Contributions

Conceptualization, C.R.-G. and D.S.-R.; methodology, C.R.-G.; writing—original draft preparation, C.R.-G. and D.S.-R.; writing—review and editing, C.R.-G., E.J.-F., N.G. and D.S.-R.; visualization, E.J.-F.; supervision, D.S.-R. All authors have read and agreed to the published version of the manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

References

1. Dakal T.C. Sharma N.K. Sharma A. Editorial: Revisiting the challenges and opportunities in cancer drug resistance Front. Mol. Biosci. 2024 11 1497754 10.3389/fmolb.2024.1497754 39403186 PMC11471640

2. Shaham S.H. Vij P. Tripathi M.K. Advances in Targeted and Chemotherapeutic Strategies for Colorectal Cancer: Current Insights and Future Directions Biomedicines 2025 13 642 10.3390/biomedicines13030642 40149618 PMC11940796

3. Rosendo-Chalma P. Díaz-Landy E.N. Antonio-Véjar V. Ortiz Tejedor J.G. Reytor-González C. Simancas-Racines D. Bigoni-Ordóñez G.D. Endometriosis: Challenges in Clinical Molecular Diagnostics and Treatment Int. J. Mol. Sci. 2025 26 3979 10.3390/ijms26093979 40362218 PMC12072088

4. Cortesi M. Rossino G. Chakrabarty A. Rossi D. Editorial: Tumor adaptation to cellular stresses: Mechanisms, biomarkers and therapeutic opportunities Front. Med. 2023 10 1268976 10.3389/fmed.2023.1268976 PMC10470628 37663659

5. Oršolić N. Jazvinšćak Jembrek M. Potential Strategies for Overcoming Drug Resistance Pathways Using Propolis and Its Polyphenolic/Flavonoid Compounds in Combination with Chemotherapy and Radiotherapy Nutrients 2024 16 3741 10.3390/nu16213741 39519572 PMC11547968

6. Fatima S. Tumor Microenvironment: A Complex Landscape of Cancer Development and Drug Resistance Cureus 2025 17 e82090 10.7759/cureus.82090 40351953 PMC12066109

7. Yun H. Dong F. Wei X. Yan X. Zhang R. Zhang X. Wang Y. Role and value of the tumor microenvironment in the progression and treatment resistance of gastric cancer (Review) Oncol. Rep. 2024 53 14 10.3892/or.2024.8847 39611496 PMC11622107

8. de Visser K.E. Joyce J.A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth Cancer Cell 2023 41 374 403 10.1016/j.ccell.2023.02.016 36917948

9. Arneth B. Tumor Microenvironment Medicina 2019 56 15 10.3390/medicina56010015 31906017 PMC7023392

10. Haque A. Brazeau D. Amin A.R. Perspectives on natural compounds in chemoprevention and treatment of cancer: An update with new promising compounds Eur. J. Cancer 2021 149 165 183 10.1016/j.ejca.2021.03.009 33865202 PMC8113151

11. Abuzahrah S.S. Elbehairi S.E.I. Bakhsh T. Atwa A. Juaid N. Mekky R.H. Marine-derived secondary metabolites in oncology: A comprehensive review Curr. Res. Biotechnol. 2025 10 100300 10.1016/j.crbiot.2025.100300

12. Pongen Y.L. Thirumurugan D. Ramasubburayan R. Prakash S. Harnessing actinobacteria potential for cancer prevention and treatment Microb. Pathog. 2023 183 106324 10.1016/j.micpath.2023.106324 37633504

13. Asma S.T. Acaroz U. Imre K. Morar A. Shah S.R.A. Hussain S.Z. Arslan-Acaroz D. Demirbas H. Hajrulai-Musliu Z. Istanbullugil F.R. Natural Products/Bioactive Compounds as a Source of Anticancer Drugs Cancers 2022 14 6203 10.3390/cancers14246203 36551687 PMC9777303

14. Kaliaperumal K. Salendra L. Liu Y. Ju Z. Sahu S.K. Elumalai S. Subramanian K. Alotaibi N.M. Alshammari N. Saeed M. Isolation of anticancer bioactive secondary metabolites from the sponge-derived endophytic fungi Penicillium sp. and in-silico computational docking approach Front. Microbiol. 2023 14 1216928 10.3389/fmicb.2023.1216928 37849927 PMC10577379

15. Sun L. Zhou W. Zhang H. Guo Q. Yang W. Li B. Sun Z. Gao S. Cui R. Modulation of Multiple Signaling Pathways of the Plant-Derived Natural Products in Cancer Front. Oncol. 2019 9 1153 10.3389/fonc.2019.01153 31781485 PMC6856297

16. Sharifi-Rad J. Ozleyen A. Boyunegmez Tumer T. Oluwaseun Adetunji C. El Omari N. Balahbib A. Taheri Y. Bouyahya A. Martorell M. Martins N. Natural Products and Synthetic Analogs as a Source of Antitumor Drugs Biomolecules 2019 9 679 10.3390/biom9110679 31683894 PMC6920853

17. Ahmed K.R. Rahman M.d.M. Islam M.d.N. Fahim M.d.M.H. Rahman M.A. Kim B. Antioxidants activities of phytochemicals perspective modulation of autophagy and apoptosis to treating cancer Biomed. Pharmacother. 2024 174 116497 10.1016/j.biopha.2024.116497 38552443

18. de Oliveira Júnior R.G. Christiane Adrielly A.F. da Silva Almeida J.R.G. Grougnet R. Thiéry V. Picot L. Sensitization of tumor cells to chemotherapy by natural products: A systematic review of preclinical data and molecular mechanisms Fitoterapia 2018 129 383 400 10.1016/j.fitote.2018.02.025 29476786

19. Talib W.H. Alsayed A.R. Barakat M. Abu-Taha M.I. Mahmod A.I. Targeting Drug Chemo-Resistance in Cancer Using Natural Products Biomedicines 2021 9 1353 10.3390/biomedicines9101353 34680470 PMC8533186

20. Zou J.-Y. Chen Q.-L. Luo X.-C. Damdinjav D. Abdelmohsen U.R. Li H.-Y. Battulga T. Chen H.-B. Wang Y.-Q. Zhang J.-Y. Natural products reverse cancer multidrug resistance Front. Pharmacol. 2024 15 1348076 10.3389/fphar.2024.1348076 38572428 PMC10988293

21. Cruz-Martins N. Advances in Plants-Derived Bioactives for Cancer Treatment Cells 2023 12 1112 10.3390/cells12081112 37190022 PMC10136607

22. Yadav J. El Hassani M. Sodhi J. Lauschke V.M. Hartman J.H. Russell L.E. Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data Drug Metab. Rev. 2021 53 207 233 10.1080/03602532.2021.1922435 33989099 PMC8381685

23. Cheng X. Xie Q. Sun Y. Advances in nanomaterial-based targeted drug delivery systems Front. Bioeng. Biotechnol. 2023 11 1177151 10.3389/fbioe.2023.1177151 37122851 PMC10133513

24. Islam S. Ahmed M.M.S. Islam M.A. Hossain N. Chowdhury M.A. Advances in nanoparticles in targeted drug delivery—A review Results Surf. Interfaces. 2025 19 100529 10.1016/j.rsurfi.2025.100529

25. Ammar M.M. Ali R. Abd Elaziz N.A. Habib H. Abbas F.M. Yassin M.T. Maniah K. Abdelaziz R. Nanotechnology in oncology: Advances in biosynthesis, drug delivery, and theranostics Discov. Oncol. 2025 16 1172 10.1007/s12672-025-02664-3 40542991 PMC12182552

26. Manna D. Sarkar D. Multifunctional Role of Astrocyte Elevated Gene-1 (AEG-1) in Cancer: Focus on Drug Resistance Cancers 2021 13 1792 10.3390/cancers13081792 33918653 PMC8069505

27. Wium M. Ajayi-Smith A.F. Paccez J.D. Zerbini L.F. The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications Cancers 2021 13 1521 10.3390/cancers13071521 33806258 PMC8037968

28. Li X. Huang X. Chang M. Lin R. Zhang J. Lu Y. Updates on altered signaling pathways in tumor drug resistance Vis. Cancer Med. 2024 5 6 10.1051/vcm/2024007

29. Garg P. Malhotra J. Kulkarni P. Horne D. Salgia R. Singhal S.S. Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells Cancers 2024 16 2478 10.3390/cancers16132478 39001539 PMC11240358

30. Xue X. Liang X.-J. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology Chin. J. Cancer 2012 31 100 109 10.5732/cjc.011.10326 22237039 PMC3777470

31. Honeywell R.J. Kathmann I. Giovannetti E. Tibaldi C. Smit E.F. Rovithi M.N. Verheul H.M.W. Peters G.J. Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance Cancers 2020 12 3322 10.3390/cancers12113322 33182766 PMC7696666

32. Szczygieł M. Markiewicz M. Szafraniec M.J. Hojda A. Fiedor L. Urbanska K. Systemic Mobilization of Breast Cancer Resistance Protein in Response to Oncogenic Stress Cancers 2022 14 313 10.3390/cancers14020313 35053477 PMC8773772

33. Fontana F. Anselmi M. Limonta P. Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor Progression Cancers 2022 14 1614 10.3390/cancers14071614 35406386 PMC8997078

34. Doldi V. El Bezawy R. Zaffaroni N. MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer Cancers 2021 13 2380 10.3390/cancers13102380 34069147 PMC8156532

35. Seborova K. Vaclavikova R. Rob L. Soucek P. Vodicka P. Non-Coding RNAs as Biomarkers of Tumor Progression and Metastatic Spread in Epithelial Ovarian Cancer Cancers 2021 13 1839 10.3390/cancers13081839 33921525 PMC8069230

36. Ruiz-Pozo V.A. Guevara-Ramírez P. Paz-Cruz E. Tamayo-Trujillo R. Cadena-Ullauri S. Frias-Toral E. Simancas-Racines D. Altuna-Roshkova Y. Reytor-González C. Zambrano A.K. The role of the Mediterranean diet in prediabetes management and prevention: A review of molecular mechanisms and clinical outcomes Food Agric. Immunol. 2024 35 2398042 10.1080/09540105.2024.2398042

37. Kar A. Agarwal S. Singh A. Bajaj A. Dasgupta U. Insights into molecular mechanisms of chemotherapy resistance in cancer Transl. Oncol. 2024 42 101901 10.1016/j.tranon.2024.101901 38341963 PMC10867449

38. Kinnel B. Singh S.K. Oprea-Ilies G. Singh R. Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer Cancers 2023 15 1320 10.3390/cancers15041320 36831661 PMC9954028

39. Gu Y. Yang R. Zhang Y. Guo M. Takehiro K. Zhan M. Yang L. Wang H. Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer Mol. Biomed. 2025 6 2 10.1186/s43556-024-00239-2 39757310 PMC11700966

40. La Rocca A. De Gregorio V. Lagreca E. Vecchione R. Netti P.A. Imparato G. Colorectal Cancer Bioengineered Microtissues as a Model to Replicate Tumor-ECM Crosstalk and Assess Drug Delivery Systems In Vitro Int. J. Mol. Sci. 2023 24 5678 10.3390/ijms24065678 36982752 PMC10059762

41. Marzagalli M. Fontana F. Raimondi M. Limonta P. Cancer Stem Cells—Key Players in Tumor Relapse Cancers 2021 13 376 10.3390/cancers13030376 33498502 PMC7864187

42. Salemme V. Centonze G. Avalle L. Natalini D. Piccolantonio A. Arina P. Morellato A. Ala U. Taverna D. Turco E. The role of tumor microenvironment in drug resistance: Emerging technologies to unravel breast cancer heterogeneity Front. Oncol. 2023 13 1170264 10.3389/fonc.2023.1170264 37265795 PMC10229846

43. Proietto M. Crippa M. Damiani C. Pasquale V. Sacco E. Vanoni M. Gilardi M. Tumor heterogeneity: Preclinical models, emerging technologies, and future applications Front. Oncol. 2023 13 1164535 10.3389/fonc.2023.1164535 37188201 PMC10175698

44. Zhu L. Jiang M. Wang H. Sun H. Zhu J. Zhao W. Fang Q. Yu J. Chen P. Wu S. A narrative review of tumor heterogeneity and challenges to tumor drug therapy Ann. Transl. Med. 2021 9 1351 10.21037/atm-21-1948 34532488 PMC8422119

45. Chen S. Wang M. Lu T. Liu Y. Hong W. He X. Cheng Y. Liu J. Wei Y. Wei X. JMJD6 in tumor-associated macrophage regulates macrophage polarization and cancer progression via STAT3/IL-10 axis Oncogene 2023 42 2737 2750 10.1038/s41388-023-02781-9 37567973 PMC10491492

46. Tang B. Zhu J. Wang Y. Chen W. Fang S. Mao W. Xu Z. Yang Y. Weng Q. Zhao Z. Targeted xCT-mediated Ferroptosis and Protumoral Polarization of Macrophages Is Effective against HCC and Enhances the Efficacy of the Anti-PD-1/L1 Response Adv. Sci. 2023 10 2203973 10.1002/advs.202203973 36442849 PMC9839855

47. Li Y. Shen Z. Chai Z. Zhan Y. Zhang Y. Liu Z. Liu Y. Li Z. Lin M. Zhang Z. Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity Gut 2023 72 2307 2320 10.1136/gutjnl-2022-329147 37507218 PMC10715532

48. Diaz Bessone M.I. Gattas M.J. Laporte T. Tanaka M. Simian M. The Tumor Microenvironment as a Regulator of Endocrine Resistance in Breast Cancer Front. Endocrinol. 2019 10 547 10.3389/fendo.2019.00547 PMC6694443 31440208

49. Reytor-González C. Simancas-Racines D. Román-Galeano N.M. Campuzano-Donoso M. Carella A.M. Zambrano-Villacres R. Marinelli T. Coppola L. Marchetti M. Galasso M. Obesity and breast cancer: Exploring the nexus of chronic inflammation, metabolic dysregulation, and nutritional strategies Food Agric. Immunol. 2025 36 2521270 10.1080/09540105.2025.2521270

50. Simancas-Racines D. Campuzano-Donoso M. Román-Galeano N.M. Zambrano-Villacres R. Memoli P. Verde L. Reytor-González C. Carbone L. Obesity and endometrial cancer: Biological mechanisms, nutritional strategies, and clinical perspectives Food Agric. Immunol. 2025 36 2510961 10.1080/09540105.2025.2510961

51. Sarno G. Reytor-González C. Frias-Toral E. Campuzano-Donoso M. Katsanos C.S. Simancas-Racines D. Navigating the weight: The impact of obesity on gastrointestinal cancer surgery and strategies for improved outcomes Semin. Cancer Biol. 2025 114 138 149 10.1016/j.semcancer.2025.06.010 40581314

52. Sarno G. Simancas-Racines D. Gargiulo A. Tedesco A. Iacone B. Reytor-González C. Parise-Vasco J.M. Angamarca Iguago J. Sarno S. Frias-Toral E. Impact of obesity on postoperative complications in colorectal cancer surgery: A systematic review and meta-analysis Semin. Cancer Biol. 2025 113 176 189 10.1016/j.semcancer.2025.05.012 40412491

53. Simancas-Racines D. Annunziata G. Verde L. Fascì-Spurio F. Reytor-González C. Muscogiuri G. Frias-Toral E. Barrea L. Nutritional Strategies for Battling Obesity-Linked Liver Disease: The Role of Medical Nutritional Therapy in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management Curr. Obes. Rep. 2025 14 7 10.1007/s13679-024-00597-6 39797961 PMC11724794

54. Reytor-González C. Annunziata G. Campuzano-Donoso M. Morales-López T. Basantes-Tituaña C. Fascì-Spurio F. Verde L. Muscogiuri G. Barrea L. Frias-Toral E. Endocrinologist’s crucial role in metabolic dysfunction-associated steatotic liver disease: A comprehensive review Minerva Endocrinol. 2025 50 209 226 10.23736/S2724-6507.24.04314-8 40116171

55. Reytor-González C. Parise-Vasco J.M. González N. Simancas-Racines A. Zambrano-Villacres R. Zambrano A.K. Simancas-Racines D. Obesity and periodontitis: A comprehensive review of their interconnected pathophysiology and clinical implications Front. Nutr. 2024 11 1440216 10.3389/fnut.2024.1440216 39171112 PMC11335523

56. Kobayashi H. Gieniec K.A. Lannagan T.R.M. Wang T. Asai N. Mizutani Y. Iida T. Ando R. Thomas E.M. Sakai A. The Origin and Contribution of Cancer-Associated Fibroblasts in Colorectal Carcinogenesis Gastroenterology 2022 162 890 906 10.1053/j.gastro.2021.11.037 34883119 PMC8881386

57. Krisnawan V.E. Stanley J.A. Schwarz J.K. DeNardo D.G. Tumor Microenvironment as a Regulator of Radiation Therapy: New Insights into Stromal-Mediated Radioresistance Cancers 2020 12 2916 10.3390/cancers12102916 33050580 PMC7600316

58. Liang L. Li W. Li X. Jin X. Liao Q. Li Y. Zhou Y. ‘Reverse Warburg effect’ of cancer-associated fibroblasts (Review) Int. J. Oncol. 2022 60 67 10.3892/ijo.2022.5357 35425996

59. Zhao Q. Huang L. Qin G. Qiao Y. Ren F. Shen C. Wang S. Liu S. Lian J. Wang D. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma Cancer Lett. 2021 518 35 48 10.1016/j.canlet.2021.06.009 34139285

60. Xiang H. Ramil C.P. Hai J. Zhang C. Wang H. Watkins A.A. Afshar R. Georgiev P. Sze M.A. Song X.S. Cancer-Associated Fibroblasts Promote Immunosuppression by Inducing ROS-Generating Monocytic MDSCs in Lung Squamous Cell Carcinoma Cancer Immunol. Res. 2020 8 436 450 10.1158/2326-6066.CIR-19-0507 32075803

61. Wang W.-Z. Cao X. Bian L. Gao Y. Yu M. Li Y.-T. Xu J.-G. Wang Y.-H. Yang H.-F. You D.-Y. Analysis of mRNA-miRNA interaction network reveals the role of CAFs-derived exosomes in the immune regulation of oral squamous cell carcinoma BMC Cancer 2023 23 591 10.1186/s12885-023-11028-5 37365497 PMC10294399

62. Miaomiao S. Xiaoqian W. Yuwei S. Chao C. Chenbo Y. Yinghao L. Yichen H. Jiao S. Kuisheng C. Cancer-associated fibroblast-derived exosome microRNA-21 promotes angiogenesis in multiple myeloma Sci. Rep. 2023 13 9671 10.1038/s41598-023-36092-6 37316504 PMC10267152

63. Zhang Z. Shang J. Yang Q. Dai Z. Liang Y. Lai C. Feng T. Zhong D. Zou H. Sun L. Exosomes derived from human adipose mesenchymal stem cells ameliorate hepatic fibrosis by inhibiting PI3K/Akt/mTOR pathway and remodeling choline metabolism J. Nanobiotechnol. 2023 21 29 10.1186/s12951-023-01788-4 PMC9878808 36698192

64. Zhang Y. Yin C. Wei C. Xia S. Qiao Z. Zhang X.-W. Yu B. Zhou J. Wang R. Exosomal miR-625-3p secreted by cancer-associated fibroblasts in colorectal cancer promotes EMT and chemotherapeutic resistance by blocking the CELF2/WWOX pathway Pharmacol. Res. 2022 186 106534 10.1016/j.phrs.2022.106534 36336217

65. Huang H. Wang Z. Zhang Y. Pradhan R.N. Ganguly D. Chandra R. Murimwa G. Wright S. Gu X. Maddipati R. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer Cancer Cell 2022 40 656 673.e7 10.1016/j.ccell.2022.04.011 35523176 PMC9197998

66. Song M. He J. Pan Q.-Z. Yang J. Zhao J. Zhang Y.-J. Huang Y. Tang Y. Wang Q. He J. Cancer-Associated Fibroblast-Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression Hepatology 2021 73 1717 1735 10.1002/hep.31792 33682185

67. Feng B. Wu J. Shen B. Jiang F. Feng J. Cancer-associated fibroblasts and resistance to anticancer therapies: Status, mechanisms, and countermeasures Cancer Cell Int. 2022 22 166 10.1186/s12935-022-02599-7 35488263 PMC9052457

68. Yu W. Lei Q. Yang L. Qin G. Liu S. Wang D. Ping Y. Zhang Y. Contradictory roles of lipid metabolism in immune response within the tumor microenvironment J. Hematol. Oncol. 2021 14 187 10.1186/s13045-021-01200-4 34742349 PMC8572421

69. Kennel K.B. Bozlar M. De Valk A.F. Greten F.R. Cancer-Associated Fibroblasts in Inflammation and Antitumor Immunity Clin. Cancer Res. 2023 29 1009 1016 10.1158/1078-0432.CCR-22-1031 36399325 PMC10011884

70. Galbo P.M. Zang X. Zheng D. Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance Clin. Cancer Res. 2021 27 2636 2647 10.1158/1078-0432.CCR-20-4226 33622705 PMC8102353

71. Glabman R.A. Choyke P.L. Sato N. Cancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy Cancers 2022 14 3906 10.3390/cancers14163906 36010899 PMC9405783

72. Bhattacharjee S. Hamberger F. Ravichandra A. Miller M. Nair A. Affo S. Filliol A. Chin L. Savage T.M. Yin D. Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts J. Clin. Investig. 2021 131 e146987 10.1172/JCI146987 33905375 PMC8159701

73. Li X. Sun Z. Peng G. Xiao Y. Guo J. Wu B. Li X. Zhou W. Li J. Li Z. Single-cell RNA sequencing reveals a pro-invasive cancer-associated fibroblast subgroup associated with poor clinical outcomes in patients with gastric cancer Theranostics 2022 12 620 638 10.7150/thno.60540 34976204 PMC8692898

74. Vimalraj S. A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions Int. J. Biol. Macromol. 2022 221 1428 1438 10.1016/j.ijbiomac.2022.09.129 36122781

75. Magar A.G. Morya V.K. Kwak M.K. Oh J.U. Noh K.C. A Molecular Perspective on HIF-1α and Angiogenic Stimulator Networks and Their Role in Solid Tumors: An Update Int. J. Mol. Sci. 2024 25 3313 10.3390/ijms25063313 38542288 PMC10970012

76. Malekan M. Ebrahimzadeh M.A. Sheida F. The role of Hypoxia-Inducible Factor-1alpha and its signaling in melanoma Biomed. Pharmacother. 2021 141 111873 10.1016/j.biopha.2021.111873 34225012

77. Henke E. Nandigama R. Ergün S. Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy Front. Mol. Biosci. 2020 6 160 10.3389/fmolb.2019.00160 32118030 PMC7025524

78. Luo Z. Tian M. Yang G. Tan Q. Chen Y. Li G. Zhang Q. Li Y. Wan P. Wu J. Hypoxia signaling in human health and diseases: Implications and prospects for therapeutics Signal Transduct. Target. Ther. 2022 7 218 10.1038/s41392-022-01080-1 35798726 PMC9261907

79. Lin S. Chai Y. Zheng X. Xu X. The role of HIF in angiogenesis, lymphangiogenesis, and tumor microenvironment in urological cancers Mol. Biol. Rep. 2024 51 14 10.1007/s11033-023-08931-2 PMC10716070 38085375

80. Manuelli V. Pecorari C. Filomeni G. Zito E. Regulation of redox signaling in HIF-1-dependent tumor angiogenesis FEBS J. 2022 289 5413 5425 10.1111/febs.16110 34228878

81. Bakleh M.Z. Al Haj Zen A. The Distinct Role of HIF-1α and HIF-2α in Hypoxia and Angiogenesis Cells 2025 14 673 10.3390/cells14090673 40358197 PMC12071368

82. Jiang Y. Zhang H. Wang J. Liu Y. Luo T. Hua H. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy J. Hematol. Oncol. 2022 15 34 10.1186/s13045-022-01252-0 35331296 PMC8943941

83. Simancas-Racines D. Reytor-González C. Frias-Toral E. Katsanos C.S. Hidalgo R. Weighty matters: Unraveling the impact of obesity on colorectal cancer and nutritional interventions Semin. Cancer Biol. 2025 114 29 40 10.1016/j.semcancer.2025.06.004 40482846

84. Pandey K. Umar S. Microbiome in drug resistance to colon cancer Curr. Opin. Physiol. 2021 23 100472 10.1016/j.cophys.2021.100472 34514218 PMC8425411

85. Veziant J. Villéger R. Barnich N. Bonnet M. Gut Microbiota as Potential Biomarker and/or Therapeutic Target to Improve the Management of Cancer: Focus on Colibactin-Producing Escherichia coli in Colorectal Cancer Cancers 2021 13 2215 10.3390/cancers13092215 34063108 PMC8124679

86. Belotti D. Pinessi D. Taraboletti G. Alternative Vascularization Mechanisms in Tumor Resistance to Therapy Cancers 2021 13 1912 10.3390/cancers13081912 33921099 PMC8071410

87. Liu X. Liu Y. Qi Y. Huang Y. Hu F. Dong F. Shu K. Lei T. Signal Pathways Involved in the Interaction Between Tumor-Associated Macrophages/TAMs and Glioblastoma Cells Front. Oncol. 2022 12 822085 10.3389/fonc.2022.822085 35600367 PMC9114701

88. Downs-Canner S.M. Meier J. Vincent B.G. Serody J.S. B Cell Function in the Tumor Microenvironment Annu. Rev. Immunol. 2022 40 169 193 10.1146/annurev-immunol-101220-015603 35044794

89. Chmiel P. Rychcik-Pazyrska P. Stec R. Defining Tumor Microenvironment as a Possible Target for Effective GEP-NENs Immunotherapy—A Systematic Review Cancers 2023 15 5232 10.3390/cancers15215232 37958406 PMC10648089

90. Zhao X. Zhu Y. He Y. Gu W. Zhou Q. Jin B. Chen S. Lin H. Unraveling the immune evasion mechanisms in the tumor microenvironment of head and neck squamous cell carcinoma Front. Immunol. 2025 16 1597202 10.3389/fimmu.2025.1597202 40438103 PMC12116449

91. Kim S.K. Cho S.W. The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment Front. Pharmacol. 2022 13 868695 10.3389/fphar.2022.868695 35685630 PMC9171538

92. Ghebremedhin A. Athavale D. Zhang Y. Yao X. Balch C. Song S. Tumor-Associated Macrophages as Major Immunosuppressive Cells in the Tumor Microenvironment Cancers 2024 16 3410 10.3390/cancers16193410 39410029 PMC11475569

93. Shah D.D. Chorawala M.R. Raghani N.R. Patel R. Fareed M. Kashid V.A. Prajapati B.G. Tumor microenvironment: Recent advances in understanding and its role in modulating cancer therapies Med. Oncol. 2025 42 117 10.1007/s12032-025-02641-4 40102282

94. Zhang H. Dai Z. Wu W. Wang Z. Zhang N. Zhang L. Zeng W.-J. Liu Z. Cheng Q. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer J. Exp. Clin. Cancer Res. 2021 40 184 10.1186/s13046-021-01987-7 34088360 PMC8178863

95. Wang H. Tian T. Zhang J. Tumor-Associated Macrophages (TAMs) in Colorectal Cancer (CRC): From Mechanism to Therapy and Prognosis Int. J. Mol. Sci. 2021 22 8470 10.3390/ijms22168470 34445193 PMC8395168

96. Bigos K.J.A. Quiles C.G. Lunj S. Smith D.J. Krause M. Troost E.G.C. West C.M. Hoskin P. Choudhury A. Tumour response to hypoxia: Understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours Front. Oncol. 2024 14 1331355 10.3389/fonc.2024.1331355 38352889 PMC10861654

97. Rømer A.M.A. Thorseth M.-L. Madsen D.H. Immune Modulatory Properties of Collagen in Cancer Front. Immunol. 2021 12 791453 10.3389/fimmu.2021.791453 34956223 PMC8692250

98. Labani-Motlagh A. Ashja-Mahdavi M. Loskog A. The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses Front. Immunol. 2020 11 940 10.3389/fimmu.2020.00940 32499786 PMC7243284

99. Zaghdoudi S. Decaup E. Belhabib I. Samain R. Cassant-Sourdy S. Rochotte J. Brunel A. Schlaepfer D. Cros J. Neuzillet C. FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer EMBO Mol. Med. 2020 12 e12010 10.15252/emmm.202012010 33025708 PMC7645544

100. Whisner C.M. Athena Aktipis C. The Role of the Microbiome in Cancer Initiation and Progression: How Microbes and Cancer Cells Utilize Excess Energy and Promote One Another’s Growth Curr. Nutr. Rep. 2019 8 42 51 10.1007/s13668-019-0257-2 30758778 PMC6426824

101. Ilerhunmwuwa N.P. Abdul Khader A.H.S. Smith C. Cliff E.R.S. Booth C.M. Hottel E. Aziz M. Lee-Smith W. Goodman A. Chakraborty R. Dietary interventions in cancer: A systematic review of all randomized controlled trials JNCI J. Natl. Cancer Inst. 2024 116 1026 1034 10.1093/jnci/djae051 38429997 PMC11223872

102. Martínez-Garay C. Djouder N. Dietary interventions and precision nutrition in cancer therapy Trends Mol. Med. 2023 29 489 511 10.1016/j.molmed.2023.04.004 37263858

103. Muscogiuri G. Verde L. Frias-Toral E. Reytor-González C. Annunziata G. Proganò M. Savastano S. Simancas-Racines D. Colao A. Barrea L. Weight loss, changes in body composition and inflammatory status after a very low-energy ketogenic therapy (VLEKT): Does gender matter? J. Transl. Med. 2024 22 949 10.1186/s12967-024-05733-3 39427162 PMC11490016

104. Reytor-González C. Zambrano A.K. Frias-Toral E. Campuzano-Donoso M. Simancas-Racines D. Mediterranean diet and breast cancer: A narrative review Medwave 2025 25 e3027 10.5867/medwave.2025.02.3027 40036698

105. Simancas-Racines D. Reytor-González C. Zambrano A.K. Annunziata G. Carella A.M. Verde L. Frias-Toral E. Guerra C.V. Hidalgo R. Unlocking the potential: Very-low-energy ketogenic therapy in obesity-related disorders Food Agric. Immunol. 2025 36 2442368 10.1080/09540105.2024.2442368

106. Reytor-González C. Simancas-Racines D. Campuzano-Donoso M. Castano Jimenez J. Román-Galeano N.M. Sarno G. Frias-Toral E. Harnessing nutrition to combat MASLD: A comprehensive guide to food-based therapeutic strategies Food Agric. Immunol. 2025 36 2496499 10.1080/09540105.2025.2496499

107. Reytor-González C. Frias-Toral E. Nuñez-Vásquez C. Parise-Vasco J.M. Zambrano-Villacres R. Simancas-Racines D. Schiavo L. Preventing and Managing Pre- and Postoperative Micronutrient Deficiencies: A Vital Component of Long-Term Success in Bariatric Surgery Nutrients 2025 17 741 10.3390/nu17050741 40077612 PMC11902093

108. Simancas-Racines D. Frias-Toral E. Campuzano-Donoso M. Ramos-Sarmiento D. Zambrano-Villacres R. Reytor-González C. Schiavo L. Preoperative Nutrition in Bariatric Surgery: A Narrative Review on Enhancing Surgical Success and Patient Outcomes Nutrients 2025 17 566 10.3390/nu17030566 39940424 PMC11820445

109. Reytor-González C. Simancas-Racines D. Román-Galeano N.M. Annunziata G. Galasso M. Zambrano-Villacres R. Verde L. Muscogiuri G. Frias-Toral E. Barrea L. Chrononutrition and Energy Balance: How Meal Timing and Circadian Rhythms Shape Weight Regulation and Metabolic Health Nutrients 2025 17 2135 10.3390/nu17132135 40647240 PMC12252119

110. Ubago-Guisado E. Rodríguez-Barranco M. Ching-López A. Petrova D. Molina-Montes E. Amiano P. Barricarte-Gurrea A. Chirlaque M.-D. Agudo A. Sánchez M.-J. Evidence Update on the Relationship between Diet and the Most Common Cancers from the European Prospective Investigation into Cancer and Nutrition (EPIC) Study: A Systematic Review Nutrients 2021 13 3582 10.3390/nu13103582 34684583 PMC8540388

111. Ruban M. Pozhidaeva E. Bolotina L. Kaprin A. The Role of Diet and Nutrition in Cancer Development and Management: From Molecular Mechanisms to Personalized Interventions Foods 2025 14 1788 10.3390/foods14101788 40428567 PMC12110988

112. Golonko A. Pienkowski T. Swislocka R. Orzechowska S. Marszalek K. Szczerbinski L. Swiergiel A.H. Lewandowski W. Dietary factors and their influence on immunotherapy strategies in oncology: A comprehensive review Cell Death Dis. 2024 15 254 10.1038/s41419-024-06641-6 38594256 PMC11004013

113. Bose S. Allen A.E. Locasale J.W. The Molecular Link from Diet to Cancer Cell Metabolism Mol. Cell 2020 78 1034 1044 10.1016/j.molcel.2020.05.018 32504556 PMC7305994

114. Mercier B.D. Tizpa E. Philip E.J. Feng Q. Huang Z. Thomas R.M. Pal S.K. Dorff T.B. Li Y.R. Dietary Interventions in Cancer Treatment and Response: A Comprehensive Review Cancers 2022 14 5149 10.3390/cancers14205149 36291933 PMC9600754

115. Wyer S. Townsend D.M. Ye Z. Kourtidis A. Choo Y.-M. Branco de Barros A.L. Donia M.S. Hamann M.T. Recent advances and limitations in the application of kahalalides for the control of cancer Biomed. Pharmacother. 2022 148 112676 10.1016/j.biopha.2022.112676 35149387 PMC9004612

116. Zhai K. Brockmüller A. Kubatka P. Shakibaei M. Büsselberg D. Curcumin’s Beneficial Effects on Neuroblastoma: Mechanisms, Challenges, and Potential Solutions Biomolecules 2020 10 1469 10.3390/biom10111469 33105719 PMC7690450

117. Augimeri G. Montalto F.I. Giordano C. Barone I. Lanzino M. Catalano S. Andò S. De Amicis F. Bonofiglio D. Nutraceuticals in the Mediterranean Diet: Potential Avenues for Breast Cancer Treatment Nutrients 2021 13 2557 10.3390/nu13082557 34444715 PMC8400469

118. Granja A. Frias I. Neves A.R. Pinheiro M. Reis S. Therapeutic Potential of Epigallocatechin Gallate Nanodelivery Systems Biomed. Res. Int. 2017 2017 5813793 10.1155/2017/5813793 28791306 PMC5534279

119. Bhavsar P. Jha L.L. Bera K. Patel S. Phytoconstituents Loaded Liposomes Fabricated Based on Box Behnken Design for Metabolic Syndrome In Vitro and In Vivo Characterization J. Nat. Remedies 2023 23 1035 1052 10.18311/jnr/2023/33735

120. Gündoğdu Ö. Şen S. Kishali N. Synthesis of Bicyclic Pyrrolidine Derivatives and their Photoluminescent Properties Biomed. J. Sci. Tech. Res. 2023 49 10.26717/bjstr.2023.49.007775

121. Lu J. Ma Y. Wu J. Huang H. Wang X. Chen Z. Chen J. He H. Huang C. A review for the neuroprotective effects of andrographolide in the central nervous system Biomed. Pharmacother. 2019 117 109078 10.1016/j.biopha.2019.109078 31181444

122. Principe D.R. Underwood P.W. Korc M. Trevino J.G. Munshi H.G. Rana A. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy Front. Oncol. 2021 11 688377 10.3389/fonc.2021.688377 34336673 PMC8319847

123. Murthy H.N. Joseph K.S. Paek K.Y. Park S.Y. Production of anthraquinones from cell and organ cultures of Morinda species Appl. Microbiol. Biotechnol. 2023 107 2061 2071 10.1007/s00253-023-12440-4 36847855

124. Shen Y.A. Lin C.H. Chi W.H. Wang C.Y. Hsieh Y.T. Wei Y.H. Chen Y.J. Resveratrol Impedes the Stemness, Epithelial-Mesenchymal Transition, and Metabolic Reprogramming of Cancer Stem Cells in Nasopharyngeal Carcinoma through p53 Activation Evid.-Based Complement. Altern. Med. 2013 2013 590393 10.1155/2013/590393 23737838 PMC3657420

125. Saiful Hakim A.R. Chee C.F. Wong T.W. Abu Kasim N.H. Nasruddin N.S. Yazid F. Exploring resveratrol’s inhibitory potential on lung cancer stem cells: A scoping review of mechanistic pathways across cancer models Med. Oncol. 2025 42 318 10.1007/s12032-025-02879-y 40637827 PMC12245983

126. Capasso L. De Masi L. Sirignano C. Maresca V. Basile A. Nebbioso A. Rigano D. Bontempo P. Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential Molecules 2025 30 654 10.3390/molecules30030654 39942757 PMC11821029

127. Banyal A. Tiwari S. Sharma A. Chanana I. Patel S.K.S. Kulshrestha S. Kumar P. Vinca alkaloids as a potential cancer therapeutics: Recent update and future challenges 3 Biotech 2023 13 211 10.1007/s13205-023-03636-6 PMC10209376 37251731

128. Bozdaganyan M. Fedorov V. Kholina E. Kovalenko I. Gudimchuk N. Orekhov P. Exploring tubulin-paclitaxel binding modes through extensive molecular dynamics simulations Sci. Rep. 2025 15 8378 10.1038/s41598-025-92805-z 40069250 PMC11897383

129. Ferdous K.A. Jansen J. Amjad E. Pray E. Bloch R. Benoit A. Callahan M. Park H.-A. Mitochondrial protective potential of fucoxanthin in brain disorders J. Nutr. Sci. 2024 13 e21 10.1017/jns.2024.16 39776519 PMC11704942

130. Ahmed S.A. Mendonca P. Elhag R. Soliman K.F.A. Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, Angiogenesis Inhibition, and Autophagy Modulation Int. J. Mol. Sci. 2022 23 16091 10.3390/ijms232416091 36555740 PMC9785196

131. Pecoraro C. Terrana F. Panzeca G. Parrino B. Cascioferro S. Diana P. Giovannetti E. Carbone D. Nortopsentins as Leads from Marine Organisms for Anticancer and Anti-Inflammatory Agent Development Molecules 2023 28 6450 10.3390/molecules28186450 37764226 PMC10537790

132. Zhao L. Zheng L. A Review on Bioactive Anthraquinone and Derivatives as the Regulators for ROS Molecules 2023 28 8139 10.3390/molecules28248139 38138627 PMC10745977

133. Wang D. Wang X.-H. Yu X. Cao F. Cai X. Chen P. Li M. Feng Y. Li H. Wang X. Pharmacokinetics of Anthraquinones from Medicinal Plants Front. Pharmacol. 2021 12 638993 10.3389/fphar.2021.638993 33935728 PMC8082241

134. Ochoa-Sanchez A. Sahare P. Pathak S. Banerjee A. Estevez M. Duttaroy A.K. Luna-Bárcenas G. Paul S. Evaluation of the synergistic effects of curcumin-resveratrol co-loaded biogenic silica on colorectal cancer cells Front. Pharmacol. 2024 15 1341773 10.3389/fphar.2024.1341773 38919255 PMC11196415

135. Ciuca M.D. Racovita R.C. Curcumin: Overview of Extraction Methods, Health Benefits, and Encapsulation and Delivery Using Microemulsions and Nanoemulsions Int. J. Mol. Sci. 2023 24 8874 10.3390/ijms24108874 37240220 PMC10219365

136. Shaharudin N.S. Surindar Singh G.K. Kek T. Sultan S. Targeting signaling pathways with andrographolide in cancer therapy (Review) Mol. Clin. Oncol. 2024 21 81 10.3892/mco.2024.2779 39301125 PMC11411607

137. Simancas-Racines D. Román-Galeano N.M. Verde L. Annunziata G. Marchetti M. Matos A. Campuzano-Donoso M. Reytor-González C. Muscogiuri G. Barrea L. Targeting Cytokine Dysregulation in Psoriasis: The Role of Dietary Interventions in Modulating the Immune Response Int. J. Mol. Sci. 2025 26 2895 10.3390/ijms26072895 40243475 PMC11988797

138. Guo H. Liu Y. Wan T. Song D. Palanisamy C.P. Geng J. Pei J. Özmen S. Abd El-Aty A.M. Toward personalized cancer management: Role of precision nutrition–diet interventions J. Funct. Foods 2024 123 106584 10.1016/j.jff.2024.106584

139. Pisoschi A.M. Iordache F. Stanca L. Cimpeanu C. Furnaris F. Geicu O.I. Bilteanu L. Serban A.I. Comprehensive and critical view on the anti-inflammatory and immunomodulatory role of natural phenolic antioxidants Eur. J. Med. Chem. 2024 265 116075 10.1016/j.ejmech.2023.116075 38150963

140. Jantan I. Haque M.d.A. Arshad L. Harikrishnan H. Septama A.W. Mohamed-Hussein Z.-A. Dietary polyphenols suppress chronic inflammation by modulation of multiple inflammation-associated cell signaling pathways J. Nutr. Biochem. 2021 93 108634 10.1016/j.jnutbio.2021.108634 33794330

141. Mileo A.M. Nisticò P. Miccadei S. Polyphenols: Immunomodulatory and Therapeutic Implication in Colorectal Cancer Front. Immunol. 2019 10 729 10.3389/fimmu.2019.00729 31031748 PMC6470258

142. Zoi V. Galani V. Lianos G.D. Voulgaris S. Kyritsis A.P. Alexiou G.A. The Role of Curcumin in Cancer Treatment Biomedicines 2021 9 1086 10.3390/biomedicines9091086 34572272 PMC8464730

143. Xu L. Zhang Y. Tian K. Chen X. Zhang R. Mu X. Wu Y. Wang D. Wang S. Liu F. Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects J. Exp. Clin. Cancer Res. 2018 37 261 10.1186/s13046-018-0929-6 30373602 PMC6206930

144. Huang X. Wang Y. Yang W. Dong J. Li L. Regulation of dietary polyphenols on cancer cell pyroptosis and the tumor immune microenvironment Front. Nutr. 2022 9 974896 10.3389/fnut.2022.974896 36091247 PMC9453822

145. Golmohammadi M. Zamanian M.Y. Al-Ani A.M. Jabbar T.L. Kareem A.K. Aghaei Z.H. Tahernia H. Hjazi A. Jissir S.A. Hakimizadeh E. Targeting STAT3 signaling pathway by curcumin and its analogues for breast cancer: A narrative review Anim. Model. Exp. Med. 2024 7 853 867 10.1002/ame2.12491 PMC11680487 39219410

146. Kötting C. Hofmann L. Lotfi R. Engelhardt D. Laban S. Schuler P.J. Hoffmann T.K. Brunner C. Theodoraki M.N. Immune-Stimulatory Effects of Curcumin on the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma Cancers 2021 13 1335 10.3390/cancers13061335 33809574 PMC8001767

147. Ameer S.F. Mohamed M.Y. Elzubair Q.A. Sharif E.A.M. Ibrahim W.N. Curcumin as a novel therapeutic candidate for cancer: Can this natural compound revolutionize cancer treatment? Front. Oncol. 2024 14 1438040 10.3389/fonc.2024.1438040 39507759 PMC11537944

148. Wu R. Wang L. Yin R. Hudlikar R. Li S. Kuo H.D. Peter R. Sargsyan D. Guo Y. Liu X. Epigenetics/epigenomics and prevention by curcumin of early stages of inflammatory-driven colon cancer Mol. Carcinog. 2020 59 227 236 10.1002/mc.23146 31820492 PMC6946865

149. Ming T. Tao Q. Tang S. Zhao H. Yang H. Liu M. Ren S. Xu H. Curcumin: An epigenetic regulator and its application in cancer Biomed. Pharmacother. 2022 156 113956 10.1016/j.biopha.2022.113956 36411666

150. Cacciola N.A. Cuciniello R. Petillo G.D. Piccioni M. Filosa S. Crispi S. An Overview of the Enhanced Effects of Curcumin and Chemotherapeutic Agents in Combined Cancer Treatments Int. J. Mol. Sci. 2023 24 12587 10.3390/ijms241612587 37628772 PMC10454892

151. Qian W. Xiao Q. Wang L. Qin T. Xiao Y. Li J. Yue Y. Zhou C. Duan W. Ma Q. Resveratrol slows the tumourigenesis of pancreatic cancer by inhibiting NFκB activation Biomed. Pharmacother. 2020 127 110116 10.1016/j.biopha.2020.110116 32428833

152. Buhrmann C. Yazdi M. Bashiri Dezfouli A. Samani Sahraneshin F. Ebrahimi S.M. Hamidollah Ghaffari S. Yaghmaie M. Barin A. Shakibaei M. Shayan P. Significant decrease in the viability and tumor stem cell marker expression in tumor cell lines treated with curcumin J. Herb. Med. 2020 22 100339 10.1016/j.hermed.2020.100339

153. Hedayati N. Safari M.H. Milasi Y.E. Kahkesh S. Farahani N. Khoshnazar S.M. Dorostgou Z. Alaei E. Alimohammadi M. Rahimzadeh P. Modulation of the PI3K/Akt signaling pathway by resveratrol in cancer: Molecular mechanisms and therapeutic opportunity Discov. Oncol. 2025 16 669 10.1007/s12672-025-02471-w 40323335 PMC12052642

154. Xie C. Liang C. Wang R. Yi K. Zhou X. Li X. Chen Y. Miao D. Zhong C. Zhu J. Resveratrol suppresses lung cancer by targeting cancer stem-like cells and regulating tumor microenvironment J. Nutr. Biochem. 2023 112 109211 10.1016/j.jnutbio.2022.109211 36370924

155. Thongchot S. Ferraresi A. Vidoni C. Salwa A. Vallino L. Kittirat Y. Loilome W. Namwat N. Isidoro C. Preclinical evidence for preventive and curative effects of resveratrol on xenograft cholangiocarcinogenesis Cancer Lett. 2024 582 216589 10.1016/j.canlet.2023.216589 38097133

156. Chitcholtan K. Singh M. Tino A. Garrill A. Sykes P. Effects of Resveratrol on In Vivo Ovarian Cancer Cells Implanted on the Chorioallantoic Membrane (CAM) of a Chicken Embryo Model Int. J. Mol. Sci. 2024 25 4374 10.3390/ijms25084374 38673959 PMC11049836

157. Guo K. Feng Y. Zheng X. Sun L. Wasan H.S. Ruan S. Chen Y.-J. Resveratrol and Its Analogs: Potent Agents to Reverse Epithelial-to-Mesenchymal Transition in Tumors Front. Oncol. 2021 11 644134 10.3389/fonc.2021.644134 33937049 PMC8085503

158. Ribeiro E. Vale N. The Role of Resveratrol in Cancer Management: From Monotherapy to Combination Regimens Targets 2024 2 307 326 10.3390/targets2040018

159. Wang Z.A. Hsu W. Liu W.R. Role of SIRT1 in Epigenetics Handbook of Nutrition, Diet, and Epigenetics Springer International Publishing Cham, Switzerland 2019 311 329 10.1007/978-3-319-55530-0_1

160. Marín V. Burgos V. Pérez R. Maria D.A. Pardi P. Paz C. The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment Int. J. Mol. Sci. 2023 24 10737 10.3390/ijms241310737 37445915 PMC10341956

161. Zhou J. Lin H. Xu P. Yao L. Xie Q. Mao L. Wang Y. Matcha green tea prevents obesity-induced hypothalamic inflammation via suppressing the JAK2/STAT3 signaling pathway Food Funct. 2020 11 8987 8995 10.1039/D0FO01500H 33001081

162. Kciuk M. Alam M. Ali N. Rashid S. Głowacka P. Sundaraj R. Celik I. Yahya E.B. Dubey A. Zerroug E. Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications Molecules 2023 28 5246 10.3390/molecules28135246 37446908 PMC10343677

163. Sheng J. Shi W. Guo H. Long W. Wang Y. Qi J. Celik I. Yahya E.B. Dubey A. Zerroug E. The Inhibitory Effect of (−)-Epigallocatechin-3-Gallate on Breast Cancer Progression via Reducing SCUBE2 Methylation and DNMT Activity Molecules 2019 24 2899 10.3390/molecules24162899 31404982 PMC6719997

164. Kamboj N. Sharma S. Kumar R. Neuroprotective insights into epigallocatechin gallate (EGCG) for neurodegenerative disorders Explor. Neurosci. 2025 4 100673 10.37349/en.2025.100673

165. Bontempo P. Capasso L. De Masi L. Nebbioso A. Rigano D. Therapeutic Potential of Natural Compounds Acting through Epigenetic Mechanisms in Cardiovascular Diseases: Current Findings and Future Directions Nutrients 2024 16 2399 10.3390/nu16152399 39125279 PMC11314203

166. Xu P. Yan F. Zhao Y. Chen X. Sun S. Wang Y. Ying L. Green Tea Polyphenol EGCG Attenuates MDSCs-mediated Immunosuppression through Canonical and Non-Canonical Pathways in a 4T1 Murine Breast Cancer Model Nutrients 2020 12 1042 10.3390/nu12041042 32290071 PMC7230934

167. Reytor-González C. Simancas-Racines D. Jiménez-Flores E. Campuzano-Donoso M. Carella A.M. Coppola L. Marchetti M. Zambrano-Villacres R. Sarno G. Oesophageal adenocarcinoma, obesity, and cancer: The role of nutrition in prevention and management Food Agric. Immunol. 2025 36 2510951 10.1080/09540105.2025.2510951

168. Nadalin P. Kim Y.G. Park S.U. Recent Studies on Berberine and Its Biological and Pharmacological Activities EXCLI J. 2023 22 315 328 Leibniz Research Centre for Working Environment and Human Factors 10.17179/excli2023-5898 37223077 PMC10201012

169. Almatroodi S.A. Alsahli M.A. Rahmani A.H. Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways Molecules 2022 27 5889 10.3390/molecules27185889 36144625 PMC9505063

170. Habtemariam S. Recent Advances in Berberine Inspired Anticancer Approaches: From Drug Combination to Novel Formulation Technology and Derivatization Molecules 2020 25 1426 10.3390/molecules25061426 32245062 PMC7144379

171. Sajeev A. Sailo B. Unnikrishnan J. Talukdar A. Alqahtani M.S. Abbas M. Alqahtani A. Sethi G. Kunnumakkara A.B. Unlocking the potential of Berberine: Advancing cancer therapy through chemosensitization and combination treatments Cancer Lett. 2024 597 217019 10.1016/j.canlet.2024.217019 38849013

172. Kou Y. Tong B. Wu W. Liao X. Zhao M. Berberine Improves Chemo-Sensitivity to Cisplatin by Enhancing Cell Apoptosis and Repressing PI3K/AKT/mTOR Signaling Pathway in Gastric Cancer Front. Pharmacol. 2020 11 616251 10.3389/fphar.2020.616251 33362566 PMC7756080

173. Rozwadowska P. Bator P. Razik M. Ramian J. Rybak J. Magiera B. Magiera K. Razik W. Anticancer properties of berberine—Analysis of the latest reports J. Educ. Health Sport 2024 61 73 86 10.12775/JEHS.2024.61.005

174. Zhang C. Sheng J. Li G. Zhao L. Wang Y. Yang W. Yao X. Sun L. Zhang Z. Cui R. Effects of Berberine and Its Derivatives on Cancer: A Systems Pharmacology Review Front. Pharmacol. 2020 10 1461 10.3389/fphar.2019.01461 32009943 PMC6974675

175. Tong Y. Zhang J. Sun N. Wang X.-M. Wei Q. Zhang Y. Huang R. Pu Y. Dai H. Ren B. Berberine reverses multidrug resistance in Candida albicans by hijacking the drug efflux pump Mdr1p Sci. Bull. 2021 66 1895 1905 10.1016/j.scib.2020.12.035 36654399

176. Goswami S. Ali A. Prasad M.E. Singh P. Pharmacological significance of Catharanthus roseus in cancer management: A review Pharmacol. Res.-Mod. Chin. Medicine. 2024 11 100444 10.1016/j.prmcm.2024.100444

177. Taub J.W. Buck S.A. Xavier A.C. Edwards H. Matherly L.H. Ge Y. The evolution and history of Vinca alkaloids: From the Big Bang to the treatment of pediatric acute leukemia Pediatr. Blood Cancer 2024 71 e31247 10.1002/pbc.31247 39120434

178. Mendonce K.C. Palani N. Rajadesingu S. Radhakrishnan K. Ayyar M. Priya L.S. Pharmacological potential of bioactive compounds in Catharanthus roseus extract: A comprehensive review Toxicol. Rep. 2025 14 101998 10.1016/j.toxrep.2025.101998 40213418 PMC11982050

179. Dai Y. Chen S.-R. Chai L. Zhao J. Wang Y. Wang Y. Overview of pharmacological activities of Andrographis paniculata and its major compound andrographolide Crit. Rev. Food Sci. Nutr. 2019 59 S17 S29 10.1080/10408398.2018.1501657 30040451

180. Paul S. Roy D. Pati S. Sa G. The Adroitness of Andrographolide as a Natural Weapon Against Colorectal Cancer Front. Pharmacol. 2021 12 731492 10.3389/fphar.2021.731492 34795581 PMC8592893

181. Li X. Tian R. Liu L. Wang L. He D. Cao K. Ma J.K. Huang C. Andrographolide enhanced radiosensitivity by downregulating glycolysis via the inhibition of the PI3K-Akt-mTOR signaling pathway in HCT116 colorectal cancer cells J. Int. Med. Res. 2020 48 0300060520946169 10.1177/0300060520946169 32787737 PMC7427152

182. Tundis R. Patra J.K. Bonesi M. Das S. Nath R. Das Talukdar A. Das G. Loizzo M.R. Anti-Cancer Agent: The Labdane Diterpenoid-Andrographolide Plants 2023 12 1969 10.3390/plants12101969 37653887 PMC10221142

183. Arsakhant P. Sirion U. Chairoungdua A. Suksen K. Piyachaturawat P. Suksamrarn A. Saeeng R. Design and synthesis of C-12 dithiocarbamate andrographolide analogues as an anticancer agent Bioorg. Med. Chem. Lett. 2020 30 127263 10.1016/j.bmcl.2020.127263 32527561

184. Cai W. Li J. Chen C. Wu J. Li J. Xue X. Design, synthesis, and anticancer evaluation of novel andrographolide derivatives bearing an α,β-unsaturated ketone moiety Bioorg. Chem. 2021 112 104941 10.1016/j.bioorg.2021.104941 33940445

185. Beesetti S.L. Jayadev M. Subhashini G.V. Mansour L. Alwasel S. Harrath A.H. Andrographolide as a therapeutic agent against breast and ovarian cancers Open Life Sci. 2019 14 462 469 10.1515/biol-2019-0052 33817182 PMC7874781

186. Vovchenko M. Alexandova V. Mustyatsa V. Gudimchuk N. Study of the Microtubule-Paclitaxel Interaction in vitro and in silico Proceedings of the International Conference “Mathematical Biology and Bioinformatics” Moscow, Russia 12–19 October 2020 IMPB RAS Moscow, Russia 2020 Volume 8 10.17537/icmbb20.30

187. Paier C.R.K. Maranhão S.S. Carneiro T.R. Lima L.M. Rocha D.D. Santos R.S. Farias K.M. Moraes-Filho M.O. Pessoa C. Natural products as new antimitotic compounds for anticancer drug development Clinics 2018 73 e813s 10.6061/clinics/2018/e813s 30540125 PMC6256996

188. Deng S. Shanmugam M.K. Kumar A.P. Yap C.T. Sethi G. Bishayee A. Targeting autophagy using natural compounds for cancer prevention and therapy Cancer 2019 125 1228 1246 10.1002/cncr.31978 30748003

189. Al-Bari M.d.A.A. Ito Y. Ahmed S. Radwan N. Ahmed H.S. Eid N. Targeting Autophagy with Natural Products as a Potential Therapeutic Approach for Cancer Int. J. Mol. Sci. 2021 22 9807 10.3390/ijms22189807 34575981 PMC8467030

190. Yang Y.-H. Mao J.-W. Tan X.-L. Research progress on the source, production, and anti-cancer mechanisms of paclitaxel Chin. J. Nat. Med. 2020 18 890 897 10.1016/S1875-5364(20)60032-2 33357719

191. Lee N. Youn K. Yoon J.-H. Lee B. Kim D.H. Jun M. The Role of Fucoxanthin as a Potent Nrf2 Activator via Akt/GSK-3β/Fyn Axis against Amyloid-β Peptide-Induced Oxidative Damage Antioxidants 2023 12 629 10.3390/antiox12030629 36978877 PMC10045033

192. Elmorsy E.M. Al Doghaither H.A. Al-Ghafari A.B. Alyamani S.A. Mohammed Z.M.S. Ebrahim N.A. Elshopakey G.E. Shabana S.M. Through its genoprotective, mitochondrial bioenergetic modulation, and antioxidant effects, Fucoxanthin and its metabolite minimize Ochratoxin A-induced nephrotoxicity in HK-2 human kidney cells BMC Nephrol. 2025 26 379 10.1186/s12882-025-04276-z 40652198 PMC12255067

193. Teng C. Wu J. Zhang Z. Wang J. Yang Y. Dong C. Wu L. Lin Z. Hu Y. Wang J. Fucoxanthin ameliorates endoplasmic reticulum stress and inhibits apoptosis and alleviates intervertebral disc degeneration in rats by upregulating Sirt1 Phytother. Res. 2024 38 2114 2127 10.1002/ptr.8057 37918392

194. Dalisay D.S. Tenebro C.P. Sabido E.M. Suarez A.F.L. Paderog M.J.V. Reyes-Salarda R. Saludes J.P. Marine-Derived Anticancer Agents Targeting Apoptotic Pathways: Exploring the Depths for Novel Cancer Therapies Mar. Drugs 2024 22 114 10.3390/md22030114 38535455 PMC10972102

195. Sasikumar P. Aparna V. Sebastian A.T. Muneer A. Prabha B. Vipin C.L. Ijinu T.P. Clinically tested marine mollusk-derived anticancer agents: Chemico-pharmacological aspects Stud. Nat. Prod. Chem. 2024 83 95 131 10.1016/B978-0-443-22214-6.00021-1

196. Mayer A.M.S. Hall M.L. Lach J. Clifford J. Chandrasena K. Canton C. Kontoyianni M. Choo Y.-M. Karan D. Hamann M.T. RSK1 vs. RSK2 Inhibitory Activity of the Marine β-Carboline Alkaloid Manzamine A: A Biochemical, Cervical Cancer Protein Expression, and Computational Study Mar. Drugs 2021 19 506 10.3390/md19090506 34564169 PMC8467814

197. Ryu B. Avalon N. Cuau M. Almaliti J. Din M.O. Brennan C. Glukhov E. Knight R. Gerwick L. Gerwick W. Cyanobacteria Join the Kahalalide Conversation: Genome and Metabolite Evidence for Structurally Related Peptides ChemRxiv 2025 1 25 10.1021/jacs.5c08818 PMC12449831 40828982

198. Flores-Holguín N. Frau J. Glossman-Mitnik D. Investigating the Chemical Reactivity of Kahalalides: A Promising Source of Therapeutic Peptides from Marine Natural Products Using Conceptual Density Functional Theory ChemistrySelect 2023 8 e202303207 10.1002/slct.202303207

199. Malik M.S. Alsantali R.I. Jassas R.S. Alsimaree A.A. Syed R. Alsharif M.A. Kulkarni K. Morad M. Althagafi I.I. Ahmed S. A Journey of anthraquinones as anticancer agents—A systematic review of recent literature RSC Adv. 2021 11 35806 35827 10.1039/D1RA05686G 35492773 PMC9043427

200. Mantareva V. Iliev I. Sulikovska I. Durmuş M. Angelov I. Cobalamin (Vitamin B12) in Anticancer Photodynamic Therapy with Zn(II) Phthalocyanines Int. J. Mol. Sci. 2023 24 4400 10.3390/ijms24054400 36901830 PMC10002512

201. Tolymbekova A. Lezina L. CD320 Receptor and Vitamin B12 as Potential Targets for Anti-Cancer Therapy Int. J. Mol. Sci. 2025 26 5652 10.3390/ijms26125652 40565117 PMC12193483

202. Rachman F. Wibowo J.T. Exploring Marine Rare Actinomycetes: Untapped Resources of Bioactive Compounds in Clinical Development BIO Web Conf. 2024 92 02012 10.1051/bioconf/20249202012

203. Roy A. Datta S. Bhatia K.S. Bhumika Jha P. Prasad R. Role of plant derived bioactive compounds against cancer S. Afr. J. Bot. 2022 149 1017 1028 10.1016/j.sajb.2021.10.015

204. Qiu Y. Chen S. Yu M. Shi J. Liu J. Li X. Chen J. Sun X. Huang G. Zheng C. Natural Products from Marine-Derived Fungi with Anti-Inflammatory Activity Mar. Drugs 2024 22 433 10.3390/md22100433 39452841 PMC11509926

205. Tamzi N.N. Rahman M.M. Das S. Recent Advances in Marine-Derived Bioactives Towards Cancer Therapy Int. J. Transl. Med. 2024 4 740 781 10.3390/ijtm4040051

206. Taylor W.F. Yanez M. Moghadam S.E. Moridi Farimani M. Soroury S. Ebrahimi S.N. Tabefam M. Jabbarzadeh E. 7-epi-Clusianone, a Multi-Targeting Natural Product with Potential Chemotherapeutic, Immune-Modulating, and Anti-Angiogenic Properties Molecules 2019 24 4415 10.3390/molecules24234415 31816878 PMC6930650

207. Chaachouay N. Synergy, Additive Effects, and Antagonism of Drugs with Plant Bioactive Compounds Drugs Drug Candidates 2025 4 4 10.3390/ddc4010004

208. Cheng Z. Zhang Z. Han Y. Wang J. Wang Y. Chen X. Shao Y. Cheng Y. Zhou W. Lu X. A review on anti-cancer effect of green tea catechins J. Funct. Foods 2020 74 104172 10.1016/j.jff.2020.104172

209. Ibrahim Fouad G. Ahmed K.A. Curcumin Ameliorates Doxorubicin-Induced Cardiotoxicity and Hepatotoxicity Via Suppressing Oxidative Stress and Modulating iNOS, NF-κB, and TNF-α in Rats Cardiovasc. Toxicol. 2022 22 152 166 10.1007/s12012-021-09710-w 34837640

210. Kunnumakkara A.B. Hegde M. Parama D. Girisa S. Kumar A. Daimary U.D. Garodia P. Yenisetti S.C. Oommen O.V. Aggarwal B.B. Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials ACS Pharmacol. Transl. Sci. 2023 6 447 518 10.1021/acsptsci.2c00012 37082752 PMC10111629

211. Reytor-González C. Zambrano A.K. Montalvan M. Frias-Toral E. Simancas-Racines A. Simancas-Racines D. Adherence to the Mediterranean Diet and its association with gastric cancer: Health benefits from a Planeterranean perspective J. Transl. Med. 2024 22 483 10.1186/s12967-024-05176-w 38773621 PMC11110331

212. Boța M. Vlaia L. Jîjie A.-R. Marcovici I. Crişan F. Oancea C. Dehelean C.A. Mateescu T. Moacă E.-A. Exploring Synergistic Interactions between Natural Compounds and Conventional Chemotherapeutic Drugs in Preclinical Models of Lung Cancer Pharmaceuticals 2024 17 598 10.3390/ph17050598 38794168 PMC11123751

213. Li Y. Chen X. He W. Xia S. Jiang X. Li X. Bai J. Li N. Chen L. Yang B. Apigenin Enhanced Antitumor Effect of Cisplatin in Lung Cancer via Inhibition of Cancer Stem Cells Nutr. Cancer 2021 73 1489 1497 10.1080/01635581.2020.1802494 32757802

214. Yang B. Chen Y. Shi J. Reactive Oxygen Species (ROS)-Based Nanomedicine Chem. Rev. 2019 119 4881 4985 10.1021/acs.chemrev.8b00626 30973011

215. Li Y. Li Y. Yao Y. Li H. Gao C. Sun C. Zhuang J. Potential of cucurbitacin as an anticancer drug Biomed. Pharmacother. 2023 168 115707 10.1016/j.biopha.2023.115707 37862969

216. Abdul Satar N. Ismail M.N. Yahaya B.H. Synergistic Roles of Curcumin in Sensitising the Cisplatin Effect on a Cancer Stem Cell-Like Population Derived from Non-Small Cell Lung Cancer Cell Lines Molecules 2021 26 1056 10.3390/molecules26041056 33670440 PMC7922800

217. Ioele G. Chieffallo M. Occhiuzzi M.A. De Luca M. Garofalo A. Ragno G. Grande F. Anticancer Drugs: Recent Strategies to Improve Stability Profile, Pharmacokinetic and Pharmacodynamic Properties Molecules 2022 27 5436 10.3390/molecules27175436 36080203 PMC9457551

218. Liu B. Zhou H. Tan L. Siu K.T.H. Guan X.-Y. Exploring treatment options in cancer: Tumor treatment strategies Signal Transduct. Target. Ther. 2024 9 175 10.1038/s41392-024-01856-7 39013849 PMC11252281

219. Hong L. Li W. Li Y. Yin S. Nanoparticle-based drug delivery systems targeting cancer cell surfaces RSC Adv. 2023 13 21365 21382 10.1039/D3RA02969G 37465582 PMC10350659

220. Chen J. Hu S. Sun M. Shi J. Zhang H. Yu H. Yang Z. Recent advances and clinical translation of liposomal delivery systems in cancer therapy Eur. J. Pharm. Sci. 2024 193 106688 10.1016/j.ejps.2023.106688 38171420

221. Amin M. Seynhaeve A.L.B. Sharifi M. Falahati M. ten Hagen T.L.M. Liposomal Drug Delivery Systems for Cancer Therapy: The Rotterdam Experience Pharmaceutics 2022 14 2165 10.3390/pharmaceutics14102165 36297598 PMC9607095

222. Ciftci F. Özarslan A.C. Kantarci İ.C. Yelkenci A. Tavukcuoglu O. Ghorbanpour M. Advances in Drug Targeting, Drug Delivery, and Nanotechnology Applications: Therapeutic Significance in Cancer Treatment Pharmaceutics 2025 17 121 10.3390/pharmaceutics17010121 39861768 PMC11769154

223. Wu K. Kwon S.H. Zhou X. Fuller C. Wang X. Vadgama J. Wu Y. Overcoming Challenges in Small-Molecule Drug Bioavailability: A Review of Key Factors and Approaches Int. J. Mol. Sci. 2024 25 13121 10.3390/ijms252313121 39684832 PMC11642056

224. Rastakhiz S. Yazdani M. Shariat S. Arab A. Momtazi-Borojeni A.A. Barati N. Mansourian M. Amin M. Abbasi A. Saberi Z. Preparation of nanoliposomes linked to HER2/neu-derived (P5) peptide containing MPL adjuvant as vaccine against breast cancer J. Cell Biochem. 2019 120 1294 1303 10.1002/jcb.27090 30378147

225. Ding Y. Wang L. Li H. Miao F. Zhang Z. Hu C. Yu W. Tang Q. Shao G. Application of lipid nanovesicle drug delivery system in cancer immunotherapy J. Nanobiotechnol. 2022 20 214 10.1186/s12951-022-01429-2 35524277 PMC9073823

226. Wen H. Fu L. Huang J. Dai Y. Wang B. Xu G. Wu L. Zhou H. Curcumin reverses doxorubicin resistance via inhibition the efflux function of ABCB4 in doxorubicin-resistant breast cancer cells Mol. Med. Rep. 2019 19 5162 5168 10.3892/mmr.2019.10180 31059026 PMC6522915

227. Buhrmann C. Shayan P. Brockmueller A. Shakibaei M. Resveratrol Suppresses Cross-Talk between Colorectal Cancer Cells and Stromal Cells in Multicellular Tumor Microenvironment: A Bridge between In Vitro and In Vivo Tumor Microenvironment Study Molecules 2020 25 4292 10.3390/molecules25184292 32962102 PMC7570736

228. Hu S. Li X. Xu R. Ye L. Kong H. Zeng X. Wang H. Xie W. The synergistic effect of resveratrol in combination with cisplatin on apoptosis via modulating autophagy in A549 cells Acta Biochim. Biophys. Sin. 2016 48 528 535 10.1093/abbs/gmw026 27084520 PMC4913517

229. Norden E. Heiss E.H. Urolithin A gains in antiproliferative capacity by reducing the glycolytic potential via the p53/TIGAR axis in colon cancer cells Carcinogenesis 2019 40 93 101 10.1093/carcin/bgy158 30418550 PMC6412115

230. Manogaran P. Beeraka N.M. Huang C.-Y. Vijaya Padma V. Neferine and isoliensinine enhance ‘intracellular uptake of cisplatin’ and induce ‘ROS-mediated apoptosis’ in colorectal cancer cells—A comparative study Food Chem. Toxicol. 2019 132 110652 10.1016/j.fct.2019.110652 31255669

231. Liu L. Fan J. Ai G. Liu J. Luo N. Li C. Cheng Z. Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells Biol. Res. 2019 52 37 10.1186/s40659-019-0243-6 31319879 PMC6637630

232. Alam M.N. Yu J.Q. Beale P. Huq F. Cisplatin in combination with emetine and patulin showed dose and sequence dependent synergism against ovarian cancer Synergy 2020 10 100060 10.1016/j.synres.2019.100060 31736447

233. Bhagya N. Prabhu A. Rekha P.D. Chandrashekar K.R. Combination of tetrandrine and cisplatin synergises cytotoxicity and apoptosis in triple negative breast cancer Synergy 2020 10 100063 10.1016/j.synres.2020.100063

234. Piska K. Koczurkiewicz P. Wnuk D. Karnas E. Bucki A. Wójcik-Pszczoła K. Jamrozik M. Michalik M. Kołaczkowski M. Pękala E. Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells—The involvement of carbonyl reductase 1 inhibition Chem. Biol. Interact. 2019 300 40 48 10.1016/j.cbi.2019.01.003 30611789

235. Rawat L. Hegde H. Hoti S.L. Nayak V. Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells Biomed. Pharmacother. 2020 128 110243 10.1016/j.biopha.2020.110243 32470748

236. Yang H. Gao Y. Fan X. Liu X. Peng L. Ci X. Oridonin Sensitizes Cisplatin-Induced Apoptosis via AMPK/Akt/mTOR-Dependent Autophagosome Accumulation in A549 Cells Front. Oncol. 2019 9 769 10.3389/fonc.2019.00769 31475112 PMC6702493

237. Cao W. Li Y. Hou Y. Yang M. Fu X. Zhao B. Jiang H.M. Fu X.Y. Enhanced anticancer efficiency of doxorubicin against human glioma by natural borneol through triggering ROS-mediated signal Biomed. Pharmacother. 2019 118 109261 10.1016/j.biopha.2019.109261 31374355

238. Zhang L.N. Xia Y.Z. Zhang C. Zhang H. Luo J.G. Yang L. Kong L.Y. Vielanin K enhances doxorubicin-induced apoptosis via activation of IRE1α-TRAF2-JNK pathway and increases mitochondrial Ca 2+ influx in MCF-7 and MCF-7/MDR cells Phytomedicine 2020 78 153329 10.1016/j.phymed.2020.153329 32896708

239. Gao H.-L. Xia Y.-Z. Zhang Y.-L. Yang L. Kong L.-Y. Vielanin P enhances the cytotoxicity of doxorubicin via the inhibition of PI3K/Nrf2-stimulated MRP1 expression in MCF-7 and K562 DOX-resistant cell lines Phytomedicine 2019 58 152885 10.1016/j.phymed.2019.152885 31009836

240. Lou C. Lu H. Ma Z. Liu C. Zhang Y. Ginkgolide B enhances gemcitabine sensitivity in pancreatic cancer cell lines via inhibiting PAFR/NF-κB pathway Biomed. Pharmacother. 2019 109 563 572 10.1016/j.biopha.2018.10.084 30399592

241. Li Y. Li X. Lu Y. Chaurasiya B. Mi G. Shi D. Chen D. Webster T.J. Tu J. Shen Y. Co-delivery of Poria cocos extract and doxorubicin as an ‘all-in-one’ nanocarrier to combat breast cancer multidrug resistance during chemotherapy Nanomedicine 2020 23 102095 10.1016/j.nano.2019.102095 31669856

242. Indorf P. Patzak A. Lichtenberger F. Drug metabolism in animal models and humans: Translational aspects and chances for individual therapy Acta Physiol. 2021 233 e13734 10.1111/apha.13734 34637592

243. Li Y. Meng Q. Yang M. Liu D. Hou X. Tang L. Wang X. Lyu Y. Chen X. Liu K. Current trends in drug metabolism and pharmacokinetics Acta Pharm. Sin. B. 2019 9 1113 1144 10.1016/j.apsb.2019.10.001 31867160 PMC6900561

244. Sohn S.-I. Priya A. Balasubramaniam B. Muthuramalingam P. Sivasankar C. Selvaraj A. Valliammai A. Jothi R. Pandian S. Biomedical Applications and Bioavailability of Curcumin—An Updated Overview Pharmaceutics 2021 13 2102 10.3390/pharmaceutics13122102 34959384 PMC8703330

245. Jakobušić Brala C. Karković Marković A. Kugić A. Torić J. Barbarić M. Combination Chemotherapy with Selected Polyphenols in Preclinical and Clinical Studies—An Update Overview Molecules 2023 28 3746 10.3390/molecules28093746 37175156 PMC10180288

246. Corsini N.S. Knoblich J.A. Human organoids: New strategies and methods for analyzing human development and disease Cell 2022 185 2756 2769 10.1016/j.cell.2022.06.051 35868278

247. Chaudhary N. La Ferlita A. Choudhary B.S. Jog E. Kazi M. Yahya S. Dalwai A. Ostwal V. Singh S. Redkar S. Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas Clin. Cancer Res. 2025 31 1359 1373 10.1158/1078-0432.CCR-24-2329 39879477

248. Zhang W. Zheng X. Patient-derived xenografts or organoids in the discovery of traditional and self-assembled drug for tumor immunotherapy Front. Oncol. 2023 13 1122322 10.3389/fonc.2023.1122322 37081982 PMC10110942

249. Aliu T.B. Obun F.E. Raji H. Badmus K. Safety Evaluation and Concerns of Natural Products in Traditional Medicine AROC Pharm. Biotechnol. 2025 5 9 17 10.53858/arocpb05010917

250. Atanasov A.G. Zotchev S.B. Dirsch V.M. Orhan I.E. Banach M. Rollinger J.M. Supuran C.T. Natural products in drug discovery: Advances and opportunities Nat. Rev. Drug Discov. 2021 20 200 216 10.1038/s41573-020-00114-z 33510482 PMC7841765

251. Simoben C.V. Babiaka S.B. Moumbock A.F.A. Namba-Nzanguim C.T. Eni D.B. Medina-Franco J.L. Günther S. Ntie-Kang F. Sippl W. Challenges in natural product-based drug discovery assisted with in silico -based methods RSC Adv. 2023 13 31578 31594 10.1039/D3RA06831E 37908659 PMC10613855

252. Heinrich M. Jalil B. Abdel-Tawab M. Echeverria J. Kulić Ž. McGaw L.J. Pezzuto J.M. Potterat O. Wang J.-B. Best Practice in the chemical characterisation of extracts used in pharmacological and toxicological research—The ConPhyMP—Guidelines12 Front. Pharmacol. 2022 13 953205 10.3389/fphar.2022.953205 36176427 PMC9514875

253. Chehelgerdi M. Chehelgerdi M. Allela O.Q.B. Pecho R.D.C. Jayasankar N. Rao D.P. Thamaraikani T. Vasanthan M. Viktor P. Lakshmaiya N. Progressing nanotechnology to improve targeted cancer treatment: Overcoming hurdles in its clinical implementation Mol. Cancer 2023 22 169 10.1186/s12943-023-01865-0 37814270 PMC10561438

254. Yu L. Jin Y. Song M. Zhao Y. Zhang H. When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy Pharmaceutics 2022 14 1589 10.3390/pharmaceutics14081589 36015215 PMC9412684

255. Sabit H. Pawlik T.M. Radwan F. Abdel-Hakeem M. Abdel-Ghany S. Wadan A.H.S. Elzawahri M. El-Hashash A. Arneth B. Precision nanomedicine: Navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery Mol. Cancer 2025 24 160 10.1186/s12943-025-02357-z 40457437 PMC12131435

256. Liu B. Liu W. Xu M. Zhao T. Zhou B. Zhou R. Zhu Z. Chen X. Bao Z. Wang K. Drug delivery systems based on mesoporous silica nanoparticles for the management of hepatic diseases Acta Pharm. Sin. B 2025 15 809 833 10.1016/j.apsb.2024.12.015 40177563 PMC11959912

257. Lee W.-H. Loo C.-Y. Traini D. Young P.M. Development and Evaluation of Paclitaxel and Curcumin Dry Powder for Inhalation Lung Cancer Treatment Pharmaceutics 2020 13 9 10.3390/pharmaceutics13010009 33375181 PMC7822152

258. Chavda V.P. Patel A.B. Mistry K.J. Suthar S.F. Wu Z.-X. Chen Z.-S. Hou K. Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer: Recent Progress and Future Challenges Front. Oncol. 2022 12 867655 10.3389/fonc.2022.867655 35425710 PMC9004605

259. Ghazal H. Waqar A. Yaseen F. Shahid M. Sultana M. Tariq M. Bashir M.K. Tahseen H. Raza T. Ahmad F. Role of nanoparticles in enhancing chemotherapy efficacy for cancer treatment Next Mater. 2024 2 100128 10.1016/j.nxmate.2024.100128

260. Yang L. Han T. Liu R. Shi S. Luan S. Meng S. Plant-derived natural compounds: A new frontier in inducing immunogenic cell death for cancer treatment Biomed. Pharmacother. 2024 177 117099 10.1016/j.biopha.2024.117099 38981240

261. Lee J. Han Y. Wang W. Jo H. Kim H. Kim S. Yang K.-M. Kim S.-J. Dhanasekaran D.N. Song Y.S. Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy Biomolecules 2021 11 1107 10.3390/biom11081107 34439774 PMC8393583

262. Ravindran Menon D. Li Y. Yamauchi T. Osborne D.G. Vaddi P.K. Wempe M.F. Zhai Z. Fujita M. EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses Pharmaceuticals 2021 14 1081 10.3390/ph14111081 34832863 PMC8618268

263. Fayyaz A. Haqqi A. Khan R. Irfan M. Khan K. Reiner Ž. Sharifi-Rad J. Calina D. Revolutionizing cancer treatment: The rise of personalized immunotherapies Discov. Oncol. 2024 15 756 10.1007/s12672-024-01638-1 39692978 PMC11655907

264. Krzyszczyk P. Acevedo A. Davidoff E.J. Timmins L.M. Marrero-Berrios I. Patel M. White C. Lowe C. Sherba J.J. Hartmanshenn C. The growing role of precision and personalized medicine for cancer treatment Technology 2018 06 79 100 10.1142/S2339547818300020 PMC6352312 30713991

265. Zheng C.-C. Gao L. Sun H. Zhao X.-Y. Gao Z.-Q. Liu J. Guo W. Advancements in enzymatic reaction-mediated microbial transformation Heliyon 2024 10 e38187 10.1016/j.heliyon.2024.e38187 39430465 PMC11489147

266. Pant A. Maiti T.K. Mahajan D. Das B. Human Gut Microbiota and Drug Metabolism Microb. Ecol. 2023 86 97 111 10.1007/s00248-022-02081-x 35869999 PMC9308113

267. Kadam O. Dalai S. Chauhan B. Guru R.R. Mitra S. Raytekar N. Kumar R. Nanobiotechnology Unveils the Power of Probiotics: A Comprehensive Review on the Synergistic Role of Probiotics and Advanced Nanotechnology in Enhancing Geriatric Health Cureus 2025 17 1 21 10.7759/cureus.80478 40225478 PMC11990693

268. Cho Y.S. Han K. Xu J. Moon J.J. Novel strategies for modulating the gut microbiome for cancer therapy Adv. Drug Deliv. Rev. 2024 210 115332 10.1016/j.addr.2024.115332 38759702 PMC11268941

269. Sholl L.M. Hirsch F.R. Hwang D. Botling J. Lopez-Rios F. Bubendorf L. Mino-Kenudson M. Roden A.C. Beasley M.B. Borczuk A. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee J. Thorac. Oncol. 2020 15 1409 1424 10.1016/j.jtho.2020.05.019 32522712 PMC8363213

270. Strickler J.H. Hanks B.A. Khasraw M. Tumor Mutat. Burd. A Predict. Immunother. Response: Is. More Always Better? Clin. Cancer Res. 2021 27 1236 1241 10.1158/1078-0432.CCR-20-3054 33199494 PMC9912042

271. Cho Y.A. Lee H. Kim D.G. Kim H. Ha S.Y. Choi Y.-L. Jang K.-T. Kim K.-M. PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score Cancers 2021 13 4659 10.3390/cancers13184659 34572886 PMC8466224

272. González-Méndez I. Sorroza-Martínez K. Cuétara-Guadarrama F. Vonlanthen M. Rivera E. An overview of theranostic nanomedicine Theranostics Nanomaterials in Drug Delivery Elsevier Amsterdam, The Netherlands 2025 1 10 10.1016/B978-0-443-22044-9.00005-X

273. Al-Thani A.N. Jan A.G. Abbas M. Geetha M. Sadasivuni K.K. Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review Life Sci. 2024 352 122899 10.1016/j.lfs.2024.122899 38992574

274. Puccetti M. Pariano M. Schoubben A. Giovagnoli S. Ricci M. Biologics, theranostics, and personalized medicine in drug delivery systems Pharmacol. Res. 2024 201 107086 10.1016/j.phrs.2024.107086 38295917

275. Manzari-Tavakoli A. Babajani A. Tavakoli M.M. Safaeinejad F. Jafari A. Integrating natural compounds and nanoparticle-based drug delivery systems: A novel strategy for enhanced efficacy and selectivity in cancer therapy Cancer Med. 2024 13 e7010 10.1002/cam4.7010 38491817 PMC10943377